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Abstract
Introduction: In Portugal, the pharmaceutical consumption is subsidized by public 
funds. The rising NHS expenditures and the recent need of cost containment policies 
emphasize the discussion on priority setting in health care and raise questions of 
which criteria are appropriate to support funding decisions. Decision-makers base 
the pharmaceutical funding grant on clinical and economical evidence. Vulnerable 
sub groups, such as chronically ill and elderly with low income, benefit of higher 
financing rates than the general population. Little is known about the preferenc-
es of the public for pharmaceutical funding criteria in Portugal. Discrete Choice 
Experiments (DCEs) are suitable for the estimation of stated preferences as they 
measure of benefit that describes the good through a bundle of attributes and lev-
els and it is based on the assumption that an individual’s valuation depends upon 
the levels of these attributes. DCE have the potential to contribute to outcome 
measurement for use in economic evaluation, uniquely allowing the investigation 
of diverse questions, such as clinical, economic and ethical. Aim: This work 
seeks to investigate criteria considered important by the Portuguese public for al-
locating resources for pharmaceuticals. In particular, we estimate the importance 
of the severity of the disease for which the treatment is indicated, the prevalence 
of the disease in Portugal, the efficacy of the pharmaceutical and the government 
costs per person treated. Method: A self-completion DCE survey, with 18 binary 
choice sets, was administered to two samples of the general population. Choice 
data are used to consider the relative importance of changes across attribute lev-
els, and to model utility scores and relative probabilities. Results: A total of 90 
individual completed the DCE. For the levels and units presented in the DCE, all 
attributes were statistically significant, in both samples. The attributes “severity 
of the disease for which the pharmaceutical is indicated” and “efficacy of the new 
pharmaceutical” had the higher utility values. The coefficient for the cost attribute 
was negative. Conclusions: This is the first DCE in Portugal that extends the dis-
cussion of prioritization in the health care sector, namely on the pharmaceutical 
funding decision, to the general population. This study sets foundation for future 
research and supports the acceptability of the public for DCEs. 
Key-words: Pharmaceuticals Funding, Pharmaceuticals Reimbursement, Stated 
Preferences, Discrete Choice Experiment.
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Resumo
Introdução: O consumo de medicamentos em Portugal, é em parte, financiado pelo 
Estado, através de um sistema de comparticipação de medicamentos. O aumento 
da despesa do SNS e a recente necessidade de implementação de políticas para 
a contenção da despesa pública enfatizam a discussão sobre os critérios apropria-
dos para fundamentar as decisões de priorização e financiamento dos cuidados de 
saúde. Atualmente, a decisão para atribuição de comparticipação de medicamentos 
baseiam-se na evidência de benefício clinico e económico. No entanto, nenhum es-
tudo investigou as preferências sociais para o financiamento de medicamentos em 
Portugal. A metodologia selecionada, escolha discreta, tem o potencial de contribuir 
de forma única para a avaliação económica na saúde, englobando critérios clínicos, 
económicos e éticos. Objetivo: O presente trabalho tem como objetivo investigar 
critérios considerados importantes pela população portuguesa para o financiamento 
de medicamentos. Em particular, estimou-se a importância dos atributos: severidade 
da doença para o qual o medicamento está indicado, prevalência da doença em Por-
tugal, eficácia do medicamento e custo para o estado por pessoa tratada. Método: Foi 
administrado um questionário, DCE, com 18 pares de alternativas, a duas amostras 
da população de Braga.
Resultados: No total, 90 indivíduos responderam ao questionário. Os atributos seve-
ridade da doença para o qual o medicamento está indicado e eficácia do medica-
mento obtiveram os valores de utilidade mais elevados. Para os níveis apresentados, 
todos os atributos fora estatisticamente significativos, em ambas as amostras. O 
coeficiente para o atributo “custo para o estado por pessoa tratada” foi negativo. 
Conclusão: Este é o primeiro estudo português a estender a discussão do financia-
mento de medicamentos à população geral. Este estudo contribui para o desenvolver 
de investigações futuras e evidencia a aceitabilidade dos DCE junto da população.
Palavras-chave: Financiamento, Medicamentos, Preferências Socias, Escolha Dis-
creta.
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Chapter 1. Introduction
1. Background
There is a general agreement  that the market mechanism fails to allocate resources 
efficiently and equitable in the health care sector (Amaya-Amaya, Gerard & Ryan, 
2008) . Hence, this task often falls to the government through public policies (Ryan, 
Scott, Reeves, Bate and Russell, 2001). In the absence of market forces as the defini-
tion of the allocation of resources, policy makers seek alternative means of choosing 
between competing demands on the health care budget. In other words, they set pri-
orities. This priority setting has always been a feature of publicly financed health care 
systems (Hauck, Smith & Goddard, 2004), but some call for a more explicit approach.
The design of health policies raises an important question: how should public funds be 
allocated balancing the available scarce resources, the unlimited demand for health 
care services and the continuing rising health care expenditures? (Ryan et al. 2001)
The European countries trust these issues to their National Health System (NHS) 
that has as a main objective the provision of medical services in line with cost-ef-
fectiveness, quality and equitable principles (Mossialos, Mrazek  & Walley, 2004).
The appropriate criteria that should be used in setting priorities in a publicly funded 
health care, remains open to debate (Bryan et al., 2002) although cost-effectiveness 
methods have become popular. 
The eventual goal of economic evaluation, in the context of health services is to make 
decisions about resources that fulfil the interests of society. It seems therefore perti-
nent that the social values that fundament the decision process should be informed by 
the preferences of a representative sample of members of the society, who pay for and 
are eligible to benefit from the resource(s). (Farrar, Ryan, Ross and Ludbrook, 2000; 
Whitty, Rundle-Thiele and Scuffham, 2008; Koonal and Shah, 2010)
In Portugal, the health expenditure represents 10.4% of the GDP while the pharmaceu-
tical expenditure represent over 15.5% on of NHS budget (INFARMED 2011). These 
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numbers, allied with the economic difficulties Portugal faces, result in a great pres-
sure on the health care budget, particularly on pharmaceutical cost containment. The 
entry and financing of new pharmaceuticals is regulated by the National Authority of 
Medicines and Health Products (INFARMED, I.P.). The allocation criterion used is the 
potential health gain produced by an intervention, often measured in terms of Quality 
Adjusted Life Years (QALYs). 
Although the exact amount is not officially defined, INFARMED is generally willing 
to pay € 30.000/QALY for reimbursement. For orphan pharmaceuticals the price 
raises to between €50.000 and €80.000 per QALY (Veiga, Correia, Meireles, Dias, 
2011). INFARMED states that the decision rule followed under this approach is the 
maximization of health gain under budget constraints (Veiga et al. 2011). However, 
the definition of the exact amount INFARMED is willing to pay has been not subject to 
public scrutiny.
Little is known in Portugal about the preferences of the public, namely about the 
subsidy of pharmaceuticals. As the public is increasingly interested and engaged into 
public policies, its values should be used to inform better and more efficient policy. 
Moreover, public involvement may help to strengthen the relationship between citizens 
and decision makers, ultimately resulting in clinical, licensing, reimbursement, and 
policy decisions that better reflect the preferences of stakeholders, especially patients 
(Whitty, Rundle-Thiele & Scuffham PA, 2008). Aligning clinical practice, drug develop-
ment, and health policy with patient preferences may also improve the effectiveness 
of health interventions, possibly improving the adoption of, satisfaction with, and ad-
herence to clinical treatments or public health program (Koonal & Shah 2009).
2. Aim
The study seeks to investigate criteria considered important by the Portuguese public 
for allocating resources for pharmaceuticals. In particular, the importance of the se-
verity of the disease for which the treatment is indicated, the prevalence of the disease 
in Portugal, the efficacy of the new pharmaceutical and the government costs per 
person treated.
There is good amount of research on the Portuguese pharmaceutical policy and fi-
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nancing. However, little is known about the preferences of the Portuguese public, 
namely about the financing of pharmaceuticals. Hence, the present study brings a 
fresh approach to the Portuguese pharmaceutical policy discussion.
3. Methods
We use a preference elicitation method, namely the discrete choice experiment (DCE), 
to elicit societal preferences.  Individuals are presented with choice sets comprising 
different hypothetical combination of new pharmaceutical attributes: severity of the 
disease for which the treatment is indicated; prevalence of the disease; efficacy of the 
new pharmaceutical and government cost per person treated.  The questionnaire was 
divided in three sections: a first part with some warm-up questions, a second section 
for the choice questions and a third one which aimed to gather information about 
demographics, health status and insurance coverage. Data were analysed with STATA 
10® and are discussed from a policy design point of view.
4. Organization And Contents
A DCE requires a multidimensional approach of theoretical and practical stages. After 
the preceding introduction and reasoning of this work, chapter two intends to describe 
the Portuguese pharmaceutical sector, at a glance. Although the discussion of the 
pharmaceutical market is out of the scope of this work, it is important for the reader 
to acknowledge the Portuguese pharmaceutical context, for a better understanding of 
the framework and the results. 
Chapter three summarizes the literature and seeks to describe the process through 
which the method was chosen. It focus on the use of DCE in health care, namely on 
pharmaceutical funding research.
Chapter four explains the method with emphasis on the main steps of the DCE. This 
includes the definition of the attributes and levels, the experimental design, the qual-
itative work that tested the questionnaire, the sample design and the survey adminis-
tration process. The presentation and discussion of the DCE are presented in chapter 
five and the conclusion that arises from them, take place on chapter six.
14
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Chapter 2. Pharmaceutical Policy 
Recent economic events had large influence on the managing of the state budget and 
the design of pharmaceutical policies. Namely, in May 2011, the Portuguese govern-
ment agreed a reform program with an obligation to enforce healthcare budget cuts 
as part of austerity measures (Carone et al., 2012). The present chapter intends to 
summarize the main features of the Portuguese pharmaceutical funding context in 
order to contextualize the research and its results.
1. Pharmaceutical Expenditures
The Portuguese health system is based in three funding systems: the National Health 
Service (NHS), special social health insurance schemes for certain professions (health 
subsystems) and voluntary private health insurance. Health is pubicly financed with 
general taxes. Nonetheless, in general, the use of health care services and health 
products, including pharmaceutical consumption, is dependent on a co-payment 
(Vogler and Leopold, 2009)
The Portuguese pharmaceutical sector has been characterized by a substantial in-
crease in expenditure since the beginning of the 1990s (Barros et al. 2011). This 
increase may be explained by demographic factors (e.g. the ageing population, devel-
opment of chronicle diseases) and medical progress factors (e.g. introduction of new 
biological pharmaceuticals, which are more expensive) (Carone et al. 2012). 
Rising health care costs as well as the global economic downturn has led healthcare 
payers to opt for austerity measures such as a reduction of healthcare budgets, price 
and reimbursement cuts, and the enhancement of generic uptake (Toumi, 2012). Re-
cently, cost containment is a crucial target of policy makers and the expenditures are 
starting to slightly decrease. Table 1 represents the evolution of the pharmaceutical 
expenditures between 2007 and 2011. In  2011, the pharmaceutical expenditures rep-
resented approximately  15,5% of the NHS budget (INFARMED, 2011), which contrast 
with the data from 2007, when the pharmaceutical expenditure was higher (17.9%). 
16
More updated data is yet to be published, but, regarding the new pharmaceutical pol-
icy, it is expected a maintenance on tendency to decrease expenditures. 
TABLE 1 – PHARMACEUTICAL EXPENDITURE (INFARMED 2011)
2007 2008 2009 2010 2011
NHS Expenditure with pharmaceuticals in 
NHS Budget
17.9% 18.3% 18.5% 17.7% 15.5%
NHS Expenditure in Medicines as a % of 
GDP
0.83% 0.85% 0.93% 0.95% 0.78%
 
2.  Pharmaceutical Policy
Several changes have been introduced to the NHS in order to reduce the public phar-
maceutical expenditure. In the past decade Portugal implemented a wave of reforms. 
To design policy towards the demand of pharmaceuticals involves sensible decisions. 
Prescribed pharmaceuticals are generally considered as a cost-effective method of 
providing health care in the majority of patients. Rather than an exhaustive pres-
entation and debate, in  this section we summarize the more relevant aspects of the 
pharmaceutical policy for the present study mainly the reimbursement policy. Details 
of pharmaceutical policy can be found in (Veiga et al 2011).  INFARMED is the entity 
responsible for the most relevant aspects of the pharmaceutical policy, mainly approv-
ing the market entry and all pharmaceuticals to be reimbursed by the NHS , as well 
as setting their co-payment levels.
2.1. Reimbursement System
Pharmaceutical funding is provided through a reimbursement system for pharma-
ceuticals listed in a positive list, currently defined in the Decree law nº 106-A of the 
1st October. The World Health Organization (WHO), 2001, presents an interesting 
document, containing guidelines on “how to develop and implement a national drug 
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policy”. These guidelines refer that a national reimbursement system is an important 
part of a drug policy and a fundamental tool to apply the principles of equitable access 
to medicines and rationalization of pharmaceutical expenditures, objectified by health 
policies. WHO (2001), points health as a human right and states that the access 
to health must include the access to pharmaceuticals, as they play a crucial role in 
health care, providing a cost-effective answer to many health problems. Furthermore, 
barriers on the access to pharmaceuticals have socioeconomic consequences, in-
creasing the human capital costs and the future health costs (Veiga et al. 2011).  The 
health care market failures, namely uncertainty, dictate the presence of a national 
reimbursement system. Uncertainty lays on the impossibility to predict illness, its 
severity or its duration. Besides, the costs related to the disease may be unaffordable, 
even to those with high incomes (Veiga et al. 2011).
Based upon equity and social fairness grounds, it is expected that a national reim-
bursement system contemplates a positive discrimination of vulnerable social groups 
such as elderly, children, chronic patients and individuals with low income. This re-
sults in higher reimbursement levels to individuals considered vulnerable, reducing 
their coinsurance rates (Veiga et al. 2011). While there are solid arguments to support 
existence of a public reimbursement system for the funding of the pharmaceutical 
consumption, its prioritization criterion remains debatable.
2.2.  Economic Evaluation Criteria
Economic evaluation methods to support decisions regarding pricing and reimburse-
ment are gaining relevance in developed countries (Tele and Groot 2009). In Portugal, 
since 1998, economic evaluation has become more important for reimbursement 
decisions, guided by official guidelines for carrying cost-effectiveness studies. Firms 
that seek financing for a pharmaceutical product are required to submit the economic 
evaluation according to the Methodological Guidelines for Economic Evaluation Stud-
ies, published by INFARMED in 1998. Companies must provide pharmacotherapeu-
tic and pharmacoeconomic information demonstrating the therapeutic added value 
(ATV) related with the alternatives already reimbursed. The report has to follow the 
methodological document. Only after that, the pharmaceutical companies can apply 
for reimbursement to INFARMED Since then, the utilization of efficiency criteria in 
reimbursement decisions decisively increased.
18
Based on the pharmacological information in these documents, INFARMED makes 
prior appraisal of the new pharmaceuticals, placing it into one of six categories that 
make it eligible for reimbursement (INFARMED, 2013):
- Medicines that contain new therapeutic entities, with innovate mechanisms of action 
and higher efficacy and tolerability than the existing treatments;
- New medicines with a similar qualitative composition to others already marketed and 
reimbursed, with the same dosage form, and at a 5% lower price than the lowest 
priced, reimbursed, non-generic drug;
- New dosage form, new doses, or new packaging of already reimbursed drugs with 
the same qualitative composition, provided that there is a therapeutic and economic 
advantage;
- New medicines which do not possess a significant therapeutic innovation nor quali-
tative composition to similar, already reimbursed medicines, but have an economic 
advantage compared to them;
- Combination products containing already reimbursed active substances, and the 
price does not exceed the sum of the prices of the same medicines when given 
alone in identical dosages;
- Combinations of active substances that don’t exist in the market alone and have 
shown advantage in clinical trials over drugs in the same therapeutic group.
The result of this evaluation is a pharmacotherapeutic report with information on: 
size of the package and strength needed; therapeutic alternatives; grade of additional 
therapeutic value (ATV), measure units of the product and alternatives (“Decree-Law 
No. 118/92, 25th June” 1992). 
The application is then analysed to evaluate the economic advantage, based on the 
information provided by the applicant. If the product does not demonstrate an ATV 
compared to the alternative the economic evaluation is only based on the comparison 
of prices (considering the differences in daily posologies) (WHO 2007). In this case, 
the new pharmaceutical must have a lower price than the comparators in order to be 
approved to enter the reimbursement list. 
Although the exact amount is not officially defined, INFARMED is generally willing to 
pay €30.000/QALY for reimbursement. To orphan pharmaceuticals the price raises 
to between €50.000 and €80.000 per QALY (Veiga et al. 2011)
Considering that the per capita income is low, and the companies do not risk placing 
most of the pharmaceuticals on the market without getting reimbursement, the reim-
19
bursement rules have come to be used as an instrument of price negotiation (Teixeira 
and Vieira 2008; WHO 2007). 
2.3.  Positive List
National reimbursement regulations are framed in an inclusive or exclusive criteria. 
The aim of the positive list is to limit the number of reimbursed pharmaceuticals. 
A positive list contains the drugs that will receive different levels of reimbursement. 
Overall, the positive list can have a cost-containment effect due to the pharmaceuti-
cals companies’ behaviour, which are likely to set lower prices in order to secure their 
revenues by an increase in volume (Tele and Groot, 2009).
After the approval of the reimbursement status, each pharmaceutical is subjected to 
a reassessment, made by INFARMED, every three years.  Criteria to delist pharma-
ceuticals include, among others, excessive prices, lower therapeutic efficacy proven 
by a pharmacoepidemiologic study and the reclassification for OTC status without 
reasons of public health that justify its reimbursement (Decree-Law No. 205/2000 
1st September).
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TABLE 2 - REIMBURSEMENT CATEGORIES (INFARMED 2012)
Reimbursement 
category
Reimbursement 
rate Criteria
Category A 90%
Essential pharmaceuticals to treat chronic diseas-
es or life-saving pharmaceuticals (100%), such as 
cancer and diabetes
Category B 67%
Medicines essential for the treatment of severe 
illness. Essential pharmaceuticals of therapeutic 
value for the treatment of serious chronic diseas-
es (such as anti-asthmatic, cardiovascular phar-
maceuticals)
Category C 35%
Non priority pharmaceuticals, with proven thera-
peutic value (such as anti-infective, vaccines not 
included in the National Vaccination Plan, immu-
noglobins, anti-parasitic)
Category D 15%
New pharmaceuticals whose therapeutic value is 
not yet proven. It is a transitional category created 
in 2000.
2.4.  Reimbursement Categories
Co-payments are the most used cost-control measures on the demand side in the 
European countries. . Cost-sharing mechanisms have been introduced mainly for two 
reasons: a) to ease the public expenditure burden on health, and b) to address the 
problem of moral hazard, namely unnecessary or frivolous use. From an economic 
point of view, co-payments are effective when price elasticity is higher, as in the phar-
maceutical field (Tele and Groot, 2009).
After the inclusion in the positive list, the drug is classified in one reimbursement 
group .The Portuguese pharmaceuticals reimbursement scheme is divided into 4 cat-
egories, as described in table 2. The legal basis of the reimbursement categories is 
settled by the Ordinance No. 924-A/2010 in which the reimbursement rates for phar-
maceuticals are defined according to its pharmacotherapeutic group. 
The reimbursement of pharmaceuticals indicated in specific pathologies or special 
groups of patients is subject to a special scheme (Table 3). Examples are the reim-
bursed pharmaceuticals for haemopilia or for Alzheimer disease (“Decree-Law No. 
205/2000 1st September” 2000; WHO 2007).  It is clear that, at least at this stage 
of pharmaceutical financing, INFARMED does apply equity principles, favouring phar-
maceuticals for chronic disease.
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TABLE 3 – SPECIAL REIMBURSE SCHEMES
Disease Pharmaceuticals covered
Co- pay-
ment 
(%)
Paramyloidosis All pharmaceuticals 100%
Lupus Phrmaceuticals included on the positive list 100%
Hemophilia Phrmaceuticals included on the positive list 100%
Hemoglobin disorders Phrmaceuticals included on the positive list 100%
Alzheimer’s disease nº 13020/2011 (2ª série), de 20 de Setembro 37% 
Manic depressive disorders Lithium carbonate 100%
Inflamatory bowel disease
Pharmaceuticals defined on Order 
nº 1234/2007 (2ª série), de 29 de 
Dezembro de 2006
90%
Rheumatoid arthritis and An-
kylosing spondylitis
Pharmaceuticals defined on Order 
n.º 14123/2009 (2ª série), de 12 
de Junho
69%
Oncologic pain
Pharmaceuticals defined on Order 
nº 10279/2008, de 11 de Março 
de 2008
90%
Non oncologic pain
Pharmaceuticals defined on Order 
nº 10280/2008 (2ª série), de 11 
de Março de 2008
90%
Medically assisted procreation Pharmaceuticals defined on Order n.º 10910/2009, de 22nd April 69%
Psoriasis Pharmaceuticals indicated for pso-riasis treatment 90%
Additionally, pensioners with low incomes have an extra co-insurance rate by the NHS. 
The rank in category A is increased by 5% and, in categories B, C and D, by 15%. This 
applies only for pensioners whose total annual income does not exceed 14 times the 
guaranteed minimum income (WHO 2007).
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Chapter 3: Literature Review
1.  The Use Of Stated Preferences In Health Care
There are several methods to elicit public preferences and the decision of which meth-
od to use depends mostly on the goods in question (Ryan et al., 2001). The prefer-
ence-based outcome is generally divided into two approaches: revealed preference 
(RP) and stated preference methods (SP).  The first one, RP method, collects behavio-
ral data by the exploration of people’s preferences as indirectly revealed through their 
choices in markets, specifically related to the value of interest. RP are difficult to use 
in the health care market for several reasons. First, willingness-to-pay (WTP) values 
for health care interventions or treatment alternatives are rarely available (Özdemir, 
2009) as health care services have public good chracteristics (Gerard et al. 2008). 
There is an agency relationship between the supplier and the patient, as the former 
will generally be better informed than the latter (Gerard et al. 2008), which contrib-
utes to bias in the RP outcome. This specific nature of health care market requires 
a different approach, which relies on stated-preference (SP) data. SP involves asking 
the same individuals to state their preferences in hypothetical markets (Gerard et al. 
2008; Louviere, Hensher and Swait 2000) and are also useful to elicit preferences for 
goods that are not yet in the market (Ryan & Skåtun 2004), allowing decision makers 
to make well documented decisions in advance. Another reason for favoring SP tech-
niques is that they are based on hypothetical choices that can be precisely specified 
in advance using a design that allows straightforward identification of all effects of 
interest (Gerard et al. 2008). This is in contrast to RP data, which cannot be controlled 
a priori so that model identification cannot be guaranteed (Amaya-amaya et al. 2008) 
as attributes are collinear in market data, making it impossible to predict the effect of 
independent variation in an attribute with RP (Kjær, 2005).
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2.  Theoretical Foundations Of The Discrete Choice Experiments
DCEs are an attribute-based approach that enables collecting SP data (Gerard et 
al. 2008). They are designed to allow individuals to express their preferences for 
non-marketed goods or goods which do not exist yet (Telser & Zweifel 2007). In a DCE, 
respondents are presented a sequence of hypothetical scenarios composed by two or 
more competing alternatives that vary along several attributes, one of which may be 
a cost attribute, as the out of pocket price of each alternative or its government cost. 
In each case, respondents are asked to indicate which of the presented scenarios 
they prefer. In this way an indifference hyper plane in attribute space is approximated 
(Telser & Zweifel 2007). 
DCE characterize a consumer’s underlying utility function, and thus may improve 
policy makers’ ability to perform benefit transfers (Gerard et al., 2008). Furthermore, 
WTP is to be inferred indirectly rather than explicitly pricing the good. This is highly de-
sirable in a health care context where, as mentioned, some individuals may refuse to 
place a monetary value on human health in the CVM format, increasing the incidence 
of protest zero bids (Gerard et al., 2008) 
The theoretical foundation of the DCE is far from being linear as it comprises research 
on axiomatic conjoint measurements, information integration theory of psychology, 
random utility theory models in economics, discrete multivariate statistical models for 
contingency (crosstab) tables, and the optimal design of statistical experiments (Kjær 
2005; Lancsar and Louviere 2008). 
The discrete choice experiment is founded in random utility theory (RUT) and is con-
sistent with Lancaster’s theory (1966) of characteristics and neoclassic economics. 
RUT plays a key role in the understanding and interpretation of the behavioural pro-
cesses examined in the DCE and assumes that utility (U) for individual i conditional on 
choice j can be decomposed into an explainable component, Vij and a non-explainable 
random component Ɛij, as in equation 1 (Lancsar and Louviere, 2008) :
U i j=V i j+εi j  ,  j=1 ,  … ,  J  
(Eq.1)
This random variation may be due to unobserved attributes affecting choice, inter-indi-
vidual differences in utilities depending upon the heterogeneity in tastes, measurement 
errors and/or functional specification (Manski, 1977). The explainable component, is 
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a function of (at least) attributes of the good and the characteristics (covariates) of 
individual choosers, often modeled as shown in equation 2 (Lancsar and Louviere, 
2008):
U i n=V X i j , β+εi j
(Eq.2)
Utility is a latent, unobserved quantity; it is assumed that the choices observed are 
indicators of utility. Respondent chooses option 1 if, and if only, its utility is higher 
than the utility of any other option in the set of J alternatives. Assuming a joint prob-
ability distribution for, the probability P that utility is maximized by choosing option 1 
(Lancsar and Louviere, 2008):
P (Y i=1)=P r o b (U i 1>U i j )
.=P r o b (V i 1+εi 1>V i j+εi j )
.=P r ob (V i 1−V i j>ε i j−ε i 1)∀  j≠1
(Eq.3)
Where Y is a random variable denoting the choice outcome. DCE models are derived 
by assuming a distribution for the random component. For example, if the errors are 
independently and identically distribute (iid) as extreme value type 1 random variates, 
this results in a conditional logit specification for the choice probabilities (Lancsar and 
Louviere, 2008):
P (Y i=1 )=
e μV i l
∑ j=1
J
e μV i j
 ,  j=1 ,  … ,  J
(Eq.4)
3. Methodology
The DCE methods allow different approaches but there are some mandatory stages 
researchers need to go through in order to obtain the appropriate outcomes. It is 
crucial to carefully define the method, with acknowledge of the available time and 
how much will it cost. Ultimately, these choices have impact on the quality of the re-
sults (Champ & Welsh 2006, Kjaer 2005). Although there is no gold standard on the 
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way to carry out a DCE, the approach taken here is the same suggested by Ryan, 
1996 and described on table 4, for its reliability, simplicity and large use on health 
care field. In our study, stage one and two are presented together (Kjaer 2005).
TABLE 4 – THE DESIGN STAGES OF A DCE 
Stage 1 Identification of attributes 
Stage2 Identification of levels 
Stage 3 Experimental design 
Stage 4 Data collection: development and administration of the survey
Stage 5 Analysis of data
3.1. Identification Of Attributes And Levels
While conducting a DCE, the researcher must focus carefully on the selection of attrib-
utes and levels that will describe the good. The DCE potential of eliciting preferences 
based on the individuals’ valuation of the diferent levels of attributes that describe a 
good is the more attractive feature on the health care market (Amaya-amaya et al. 
2008). While a DCE can not incorporte all relevant attributes, it is important to include 
the most relevant ones, that are meaningful for respondents and policy makers. If an 
important attribut is ommited, respondents can make assuptions about it, affecting 
the validity of the model estimated. This is an important issue to be assessed using 
qualitative work, such as pilot studies (Kløjgaard et al. 2012; Lancsar & Louviere 
2006). The combination of the set of attributes must be able to describe what the 
choice is about, and the attributes must be chosen so that respondents will be willing 
to make trade-offs between them, following the latent economic theretical framework 
with compensatory decision-making. Further, and although it may sound appelaing 
to include a lot of attributes, researcher may guarantee that a limited number of at-
tributes is included, in order to keep a simple and understandable task and to keep 
respondents commited to it. When defining the levels of each attribute, it is important 
to remain focus that, as the attributes’ levels must be relevant and easy to compre-
hend. Besides, the range selected for the levels must allow for the trade-offs between 
them, while still being plausible for respondetns. In other words, a good experiment 
is one that balances a sufficiently rich set of attributes and choice sets, with enough 
variation in the attribute levels therefore being able to produce meaningful trade offs 
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(Amaya-amaya, Gerard, and Ryan 2008).
The best way to enhance all the desirable features of attributes and levels is to perform 
a good amount of qualitative work (Kløjgaard et al.2012). Qualitative work includes 
gathering information from various sources such as focus groups, interviews, expert 
opinions and literature review. (Kløjgaard et al. 2012). 
3.1.1. The Cost Attribute
The cost attribute is a quantitative constrained and negatively valued attribute with a 
distinct role in DCE. Its inclusion provides the DCE an elicitation procedure for willing-
ness-to-pay (WTP) or willingness to accept compensation (WTAC) for an improvement 
(or deterioration) of one of those attributes. This implies that benefits are estimated in 
monetary terms and causes the DCE to be consistent with welfare economics (i.e. the 
potential Pareto improvement condition) (Kjær 2005). 
Inclusion of a cost attribute makes it possible to indirectly obtain the respondent’s 
WTP for either the good in its entirety (an alternative) or the respondent’s WTP for 
the attribute respectively, i.e. marginal WTP (also termed part worth or implicit price) 
(Kjær 2005). Results from different studies can then be compared and - on the 
grounds of economic efficiency - used in priority-setting. Rather than showing the 
price of the good, WTP is estimated indirectly. This is highly desirable in a health care 
context where, as mentioned, some individuals may refuse to place a monetary value 
on human health in the CVM format, increasing the incidence of protest zero bids 
(Gerard et al., 2008)
The use of cost to estimate WTP raises questions about the definition of the cost at-
tribute in a collectively funded health care system, where the inclusion of cost might 
result in the scenarios being considered unrealistic and immoral (Ryan, 1999). Most 
health care services in Portugal, are paid at the point of consumption as a co-pay-
ment, that is, part of the costs are supported by public funds, while the remaining is 
financed through user payment (Barros, 2011).  Marginal WTP is simply the marginal 
rate of substitution in which the numeraire is the cost attribute. The estimation of wel-
fare is based on using the coefficient of the cost attribute to assess the marginal utility 
of income (Kjær, 2005).  Costs can take many different forms in a DCE, including 
options such as consumer price, transportation cost, salary, donation, tax payment, 
tax payment in a referendum context, etc. (Kjær 2005).
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3.2. Experimental Design
The experimental design consists in framing the selected attributes and levels into 
choice sets (Kjær 2005). This stage focus on the design of the hypothetical choice 
sets, including the formation and pairing of alternatives within choice sets. One of 
the crucial objectives of the experimental design is to create the DCE in such a way 
that the number of alternatives is minimized while being able to infer utilities for all 
possible alternatives – which implies keeping the choice task simple to the respond-
ents and at the same time being able to extract all the necessary information from 
the choices (Kjær 2005). A designed experiment is therefore a way of manipulating 
attributes and their levels to permit rigorous testing of certain hypotheses of interest 
(Louviere et al. 2000). 
The total number of possible choice sets, the full factorial, depends directly of the 
number of attributes and levels, with an exponential relationship - the number of 
possible alternatives increases exponentially when the number of attributes and levels 
increases (number(#) of alternatives = #levels^#attributes). For example, if there are 
five attributes, three with four levels and two with two levels, the full factorial produces 
256 combinations. Commonly, it is not possible to present respondents with all possi-
ble alternatives and a reduction of the number of choice sets must be done.  First of 
all, it is important to reduce the number of attributes and level to a minimum. Next, 
methods exist that can reduce the number of alternatives included in the question-
naire, while keeping the statistical properties of the design. One such method is the 
use of orthogonal arrays. Orthogonal designs are based on orthogonal arrays from 
design catalogues (e.g. Hahn and Shapiro,1966), statistical programs (e.g. SPEED, 
(Bradley, 1991); SPSS, (SPSS Inc., Chicago, IL, USA)) or web-sites (Sloane, 2009). 
These arrays have the properties of orthogonality (attributes are statistically independ-
ent of one another) and level balance (levels of attributes appear an equal number of 
times). The profiles obtained from the orthogonal design are the choices for a binary 
DCE (de Bekker-Grob, Ryan & Gerard 2012). However, it is important to be aware that 
all fractional designs involve some loss of statistical information. This loss of informa-
tion can sometimes be significant, as fractional factorial designs limit the ability to 
take higher order effects into account, i.e. interactions between two or more attributes 
(Louviere et al. 2000).
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3.2.1. Ensuring Design Efficiency
As mentioned, the use of a fractional design compromises the amount of information 
collected and the quality of such information. In order to minimise biases, it is impor-
tant to test the design for its efficiency. What appears to be important is the pairing of 
the alternatives into choice sets. The pairing of alternatives needs to be made in such 
a way that the differences in attribute levels for each choice set are not multi-correlat-
ed. In addition, as only a fraction of the total possible alternatives is to be presented to 
the respondents in fractional factorial design, the selection of alternatives also needs 
to considered in the light of design efficiency. Theory supports the satisfaction of 
some properties to ensure the maximum statistical efficiency in choice design (i.e. the 
extraction of maximum information from the choice task). Together, these principles 
are called design efficiency, also termed D-efficiency. D-efficiency relates to the design 
matrix in such a way that efficiency is maximized when the size of the covariance ma-
trix of the estimated parameters is minimized. To optimize D-efficiency, four principles 
need to be considered simultaneously. Improving any principle, holding the others 
constant, improves efficiency. In many cases it is impossible to create a design that 
satisfies all four principles, as some of the principles might conflict with each other 
(Huber & Zwerina 1996). 
Level balance simply means that the levels of an attribute occur with equal frequency 
in the design, e.g. each level of a four-level attribute should occur in precisely one-
fourth of the included alternatives. This ensures that all levels are weighted equally 
in the trade-off options that the respondent faces (Huber & Zwerina 1996. The use 
of a block design or a fractional factorial design, level balance needs to be taken into 
consideration in order to optimize efficiency.
Orthogonality is an important part of D-efficiency. Orthogonality is respected when the 
joint occurrence of any two levels of different attributes appears in profiles with fre-
quencies equal to the product of their marginal frequencies (Huber & Zwerina 1996). 
Orthogonality is thus satisfied when the difference in the levels of each attribute varies 
independently over choice sets, meaning that the levels of the attributes vary in a 
criss-cross manner. As ‘pure’ optimal orthogonal designs are only available for a very 
small number of very specific problems, the primary purpose is to optimize the design 
as best one can by minimising multicollinearity (Kuhfeld et al. 1994). A high degree 
of multicollinearity will result in a design in which unique estimates of the parameters 
cannot be obtained, making it impossible to draw any statistical inferences, i.e. hy-
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pothesis testing, from the sample
Minimal overlap relates to the statistical properties when pairing the alternatives. A 
design has minimal overlap when a level does not repeat itself in a choice set. In 
order to optimize orthogonality of the level differences, the scenarios are matched to 
ensure minimal overlap (i.e. optimal orthogonality ensures minimal overlap). Minimal 
overlap is important in choice designs, because the contrast between attribute levels 
is only meaningful as differences within a choice set. Minimal overlap ensures that 
the probability of an attribute level repeating itself in each choice set is as small as 
possible, and thus maximizes the information obtainable from the choice sets (Huber 
& Zwerina 1996).
Utility balanced is present when the utilities of alternatives within each choice set are 
approximately equal. To achieve this, the researcher needs to take the utility weights 
of the attributes into account when designing the DCE. The rationale for this principle 
is to ensure that respondents are actually trading. The efficiency gain arises because 
choices between alternatives that have similar utility provide better information about 
the coefficients. This means that two alternatives that differ in their levels but have 
approximately the same utility are more likely to ensure that the respondents are 
placed in a situation in which they are forced to trade. Application of the utility bal-
ance concept thus implies that the impact on choices of small differences in utility is 
registered resulting in more precise parameter estimates. What makes this principle 
troublesome, however, is that it requires prior estimates of the coefficients. There are 
several ways to generate useful sets of prior estimates. The most used method is to 
conduct a small pilot study to generate tentative estimates. Huber & Zwerina (1996) 
have shown that the incorporation of the utility balance principle increases efficiency 
of the DCE.
3.3. Data Collection
This section involves all the remaining issues that need to be considered before the 
questionnaire is presented to the respondents (Kjaer,2005). This includes several 
decisions such as the lay-out, whether to include an opt-out alternative, the inclusion 
of socio-demographic questions and warm-up questions.
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3.3.1. Opt-Out Choice
One important issue to consider while designing a DCE is whether to include or not an 
opt-out choice. Opt-out choice allows the possibility for the respondent not to choose 
any of the alternatives in the choice set, as demonstrated in figure1. There is literature 
supporting both decisions and the reasoning for the choice stands mostly on the na-
ture of the experiment (Kjaer, 2005). 
The inclusion of an opt-out alternative in DCE is becoming popular , as it allows for 
realism (deBekker-Grob et al., 2012).  Ryan and Skatun (2004), explain that, in the 
health care context, individuals may prefer not to take-up certain treatments or ser-
vices, whatever the level of attributes of the service, or prefer to participate only for 
certain levels of attributes.
FIGURE 1 - TEMPLATE OF A CHOICE SET INCLUDING AN OPT-OUT ALTERNATIVE
CHOICE 1
Treatment A Treatment B No treatment
Total treatment duration 4 years 6 years 0 years
Amount of relief Little relief Complete relief No relief
Side effects Yes Yes No
Total cost 350 € 900 € 0 €
Which treatment you prefer?
A
o
B
o
None
o
Taking the example in Figure 1, if the maximum willingness to pay of a respondent is 
300€, he would, in such choice set, opt for the “none” alternative. If the design did not 
allow for an opt-out choice, a forced answer would result in overestimates (identifying 
demanders that would opt-out) Ryan and Skatun, 2004). Nonetheless, the omission 
of the opt-out alternative is still considered in the heath care market DCEs. Firstly, re-
spondents may tend to avoid difficult responses such as ethical ones, using heuristics 
to make the task easier. (Kjaer, 2005). Additionally, allowing respondents to select an 
opt-out option provides less information on respondents’ relative preferences for the 
attributes in the hypothetical alternatives. Forced experiments constrain respondents 
to express a preference (i.e., make a trade-off among attributes) even when both 
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alternatives are unattractive (Mentzakis, Stefanowska & Hurley 2011). Hensher, Rose 
and Greene (2005), argue that such a design is preferred when the objective of the 
study is to examine the impact of the relationships different attribute levels have upon 
choice. For the present study, it was decided to design a forced-choice DCE as the 
investigation sets on ethical and policy principles.
3.3.2. Introductory Text
Before the respondents answer the DCE, it is important to firs introduct them to the 
task. The introductory text should define the aim of the study, the importance of 
the respondents’ participation on such study and why he was selected to participate 
(Kjaer 2005).Then, an introduction to the task, including the time it takes to complete 
the questionnaire and the instructions should also be a part of the introductory text 
(Benett and Blamey 2001). Adding an example of an answered choice set and warm-
up questions may increase the validity of the responses (Kjaer 2005) 
3.3.3. Sampling
The sample design specifies the population of interest, the sampling frame, and the 
technique for drawing a sample from the sampling frame. How the survey is adminis-
tered the survey mode -- will impact how a sample is drawn (Champ & Welsh 2006).
 The mailed questionnaire approach is – for good reason – by far the most widespread 
data collection method for DCEs in many research areas, including health economics. 
Some of the advantages with this method are the relatively small cost compared to 
the amount of information gathered and the fact that respondents can chose to com-
plete the questionnaire when it suits them. However this method tends to result in low 
response rates and thus sampling bias. A postal questionnaire limits the complexity 
of the choice task as the respondents must be able to answer the questions without 
help. Furthermore, the questionnaire needs to be written in simple language in order 
not to discriminate against individuals who are unused to completing forms and un-
derstanding written material. (Champ & Welsh 2006. Kjaer, 2005)
The choice of sampling frame that is to be used to generate potential respondents (the 
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survey sample) will depend upon the nature of the particular application. The sam-
pling frame defines the universe of respondents from which a finite sample is drawn 
to whom the data collection instrument will be administered (Louviere et al. 2000). 
If the study intends to examine the use value of asthma medication, then the most 
appropriate frame would be asthma patients. If the aim of the study is to examine use 
as well as non-use and option value, however, then the appropriate frame would be 
the general public.
Based on the sampling frame, the sampling strategy and sample size are determined. 
One sampling strategy is simple random sampling, in which all individuals from the 
sample frame have equal opportunity to be chosen as potential respondents; anoth-
er sampling strategy might be dividing the frame into groups, each representing a 
portion of the population, depending upon characteristics such as sex, income, resi-
dential location etc. (Louviere et al. 2000). It is possible to determine the appropriate 
sample size by using of elementary statistics and can be calculated through online 
services. In a mailed survey, the size of the sample depends on the number of ques-
tions given each respondent, the size of the population, and the statistical power that 
is required of the model derived. Bennett & Blamey (2001) state that the minimum 
size of a sub-sample should be in the order of 50 respondents, depending on the sta-
tistical power that is necessary for the estimation procedure. Furthermore, the sample 
size will be highly dependent on the expected response rate. To increase sample size 
(when using postal questionnaires), it might be appropriate to send out a reminder in 
the event of non-response.
3.4. Data Analyses
3.4.1 Data input
After the data are collected, it needs to be organized and set into a computerized 
database. Each choice set contains two forms of information: the attribute levels of 
each alternative, and which of the given alternatives has been chosen. To estimate 
the model, each attribute is handled as a variable containing different levels and each 
level has to be coded in order to estimate the importance of each attribute, i.e. the 
marginal values and trade of ratios (Louviere and Hensher 2000). When designing a 
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DCE it is important to consider how the exploratory variables are going to be coded. 
Dummy variables are used to account for this approach, and the least desirable option 
defined acts as a reference case. A priori the coefficients for severity of the disease 
for which the treatment is indicated, prevalence of the disease and efficacy of the new 
pharmaceutical are expected to have a positive sign, indicating an increase in utility 
(probability of being chosen for funding) relative to the reference case (constant). The 
use of dummy variables is helpful in interpreting the findings of the study, at a policy 
level, providing a meaningful reference case for a health policy audience (Louviere and 
Hensher 2000 ; Green and Gerard 2009).
3.4.2 Econometric Analyses
In econometric literature conditional logit models are often employed estimate the 
choice models (Greene, 2003). It differs from ordinary logistic regression in that the 
data are divided into groups and, within each group, the observed probability of posi-
tive outcome is either predetermined due to the data construction (such as matched 
case–control) or in part determined because of unobserved differences across the 
groups (Gould, 2000). This is in line with the underlying RUT. Thus, the likelihood 
of the data depends on the conditional probabilities, that is, the probability of the 
observed pattern of positive and negative responses within group conditional on that 
number of positive outcomes being observed. Terms that have a constant within-group 
effect on the unconditional probabilities — such as intercepts and variables that do not 
vary — cancel in the formation of these conditional probabilities and so remain unes-
timated). In this model, an individual is faced with an array of alternatives and must 
choose one. Individual taste can be captured in conditional logit models as long as it 
varies systematically with respect to observed variables (McFadden, 1973). 
Once a satisfactory model has been estimated, the results obtained can be used to 
simulate outcomes that can be used in policy analysis or as components of decision 
support tools. 
Furthermore, DCE allow estimation of trade-offs that respondents make between at-
tributes, defined as marginal rates of substitution (MRS) (Lancsar and Louviere 2008; 
Ryan 1999). Following the standard consumer theory, MRS is calculated comparing 
the estimated coefficients of two attributes. MRS indicates the trade-off between two 
attributes that characterize the good and thus the mutual importance of the attributes 
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in question. Holding the overall utility level constant:
∂V i=β∂ xi=0
(Eq.5)
And MRS is calculated through equation 6:
M R S12=
−d xi 1
d xi 2
=
β1
β2
(Eq.6)
When one of the attributes is a cost attribute, the MRS indicates the willingness-to-pay 
(WTP) for a change in the qualitative attribute, i.e. the marginal willingness-to-pay 
(MWTP). Let the price attribute be denoted as p. As income cancels out in linear price 
models (hence the negative sign of the cost variable in equation 7), marginal WTP is 
derived (Ryan et. al 2008):
(Eq.7)
Applications of DCE to economic policy (e.g. health and health care) are often targeted 
to predictions of behaviour, generating welfare measures or both. This is done by the 
comparison of the relative importance of the good attributes.  The probability that 
respondents will choose each alternative in a choice set is calculated using equation 
3, a conditional logit specification for the choice probabilities which allows comparison 
of the impact of each attribute in a common metric.         
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4. Discrete Choice Experiments In Pharmaceutical Funding Decisions: 
A Review Of The Literature
A comprehensive electronic search was carried out to identify published studies using 
DCEs within the pharmaceutical funding context. Portuguese and English language 
studies, between January 1992 and March 2013, were searched through MEDLINE, 
SCOPUS and RePEc database. Studies that matched the required criteria were se-
lected, that is, that included a stated preference study to investigate preferences for 
funding decision of pharmaceuticals. Search strategies were formulated for individual 
databases using the following keywords: ‘discrete choice’ or ‘discrete choice experi-
ment’ or ‘discrete choice analysis’ or ‘discrete choice modelling’ or ‘conjoint’ or ‘con-
joint analysis’ or ‘stated preference method’ AND ‘pharmaceuticals’ or ‘medicines’ or 
‘drugs’ or ‘pharmaceutical funding’ or ‘pharmaceutical funding criteria’ or ‘pharma-
ceutical funding decisions’ or ‘reimbursement’ or ‘pharmaceutical reimbursement’. 
There are a limited number of DCE experiments eliciting preferences for pharmaceu-
tical funding decisions. The few existing studies were, however, crucial in elucidating 
the suitable methods, some of the motivational factors behind choosing treatments 
and supporting the attributes selection and shaping the design.  
Presented in table 5 are the four research articles found that matched the defined 
criteria.  The table is organized according to the target population of the study. 
The first presented study, conducted by Whitty et al. (2008), seeks to quantify criteria 
considered important by the Australian public for allocating resources for pharma-
ceuticals. A DCE was administered to two samples of adults in Australia. A total of 
four attributes were selected, based on the principal that public are willing to trade 
between the individual components of effectiveness (that is, survival, quality of life 
(QoL), and chance of success) for the treatment of others. Further, this study aims to 
investigate the importance of government costs in prioritizing healthcare, including a 
government cost attribute. According to their findings, the Australian public view the 
QoL after treatment, survival after treatment and chance of success associated with 
a new pharmaceutical to be important considerations when funding pharmaceuticals 
for the treatment of others suffering a severe disease. Furthermore, this study con-
cludes that, when framed in terms of a government tax fund payment vehicle, the cost 
of the pharmaceutical is important to the respondents. 
An interesting point of view is given by Diaby et al. (2011), with the investigation phy-
sicians’ preferences when selecting reimbursable drugs and the analyzes of trade-offs 
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between criteria for formulary listing in Côte d’Ivoire. In order to do so, a DCE was ad-
ministered, considering four attributes: cost effectiveness, severity of the disease for 
which the treatment is indicated, social class and age. Respondents’ relative weight-
ings of four criteria were to be significant in selecting reimbursable drugs, being cost 
effectiveness, severity of the disease and social class the more relevant, in this exact 
order. This work sets foundation on studies that have demonstrated the feasibility 
of simultaneously accounting for efficiency, equitity and social criteria in a way that 
allows a rank ordering of health interventions.
Another study focusing on elicitation of preferences of health care professionals was 
held by the All Wales Medicines Strategy Group (AWMSG), which is a Welsh Govern-
ment-funded body consigned to appraise new medicines for use in NHS Wales when 
NICE guidance is not imminent. The primary aim of this DCE was to explore the 
preferences of AWMSG appraisal committee members for specific new medicines 
adoption criteria and their efficiency trade-offs. Moreover, it aims included exploration 
of the external validity of the DCE by comparing appraisal committee members’ hy-
pothetical recommendations against actual AWMSG recommendations for the use of 
new medicines in Wales. The conclusions set that QALY maximisation and economic 
efficiency are not the only considerations of committee members when making rec-
ommendations on the use of medicines in Wales, as respondents were willing to trade 
over other attributes.
Finally, Whitty et al., 2011, carried out a pilot DCE in Australia to test the concept of 
evaluating the consistency of public and decision maker preferences for the public 
subsidy of pharmaceuticals. Here the preferences of members of a pharmaceutical 
funding decision-making body are compared with those of the public on whose behalf 
decisions are made. The elicitation of preferences was based on the relative impor-
tance of gains in survival, quality of life (QOL), chance of response success and gov-
ernment costs in pharmaceutical funding decisions. The DCE was administered to a 
sample of the Australian public and members of the Pharmaceutical Benefit Advisory 
Committee and its Economic Subcommittee. For both samples, increased survival, 
QOL and chance of response success, and a reduction in costs and uncertainty (de-
cision makers only), were relevant and increased the likelihood that a pharmaceutical 
would be chosen for funding. Moreover, both samples were more likely to fund a phar-
maceutical that was used for the treatment of severe illness. Besides pointing out the 
relative importance of decision criteria, this study suggests the consistence of funding 
decisions for pharmaceuticals with the preferences of society.
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TABLE 5 – SUMMARY OF THE LITERATURE REVIEW FOR THE DCE IN PHAMACEUTICAL FUNDNG DECISIONS
Study/coun-
try
Study focus Attributes
Study design and estimation 
method
Key findings and conclusions
Public Preferences
Whtty et al. 
2008. Australia
Public preferences for allo-
cation resources for phar-
maceuticals 
Chance of success, Survival, Quality of 
life, Additional cost
Fractional factorial additive main 
effects design obtained from 
SPSS. Multinominal logit (MNL) 
model.
Public consider  QoL after treatment, survival after 
treatment and chance of success of  a new pharma-
ceutical  important attributes when funding pharma-
ceuticals for the treatment of others suffering a severe 
illness.
Decision Makers/Health Professionals Preferences
Diaby et al, 
2011. Canada
Preferences of physicians 
in Côte d’Ivoire when se-
lecting reimbursable phar-
maceuticals
Cost effectiveness of treatments, severity 
of the disease, age and social class
Optimal design for proposed by 
Street et al, 2005. Binary logistic 
regression, STATA 8.0
Preferences of physicians in Côte d’Ivoire are based 
on cost effectiveness, severity of disease, and social 
class.
W. Linley, D. 
Hughes, 2013. 
UK
Preferences of All Wales 
Medicines Strategy Group 
(AWMSG) appraisal com-
mittee and appraisal 
sub-committee (New Med-
icines Group) members 
(‘appraisal committees’) 
for specific new medicines 
adoption criteria
Main impact of disease before treat-
ment, annual number of patients to 
be treated, QALYs gained per treat-
ed patient, incremental cost per 
QALY gained, uncertainty in cost 
effectiveness is thoroughly explored 
Fractional factorial de-
sign, we therefore used an 
orthogonal main effects plan 
from Shaphira’s catalogue, 1996. 
Conditional logit, main effects 
only, STATA10.1
A willingness to trade the cost effectiveness and QALY 
gains against other factors indicates that economic 
efficiency and QALY maximisation are not the only 
considerations of committee members when making 
recommendations on the use of medicines in Wales
Public Vs. Decision Makers Preferences
Whitty et al. 
(2011) Aus-
tralia
Evaluate the consistency of 
public and decision maher 
preferences for the publc 
subsidy of pharmaceuticals
Chance of response success, survival, 
quality of life (QoL), cost to government 
per person treated. Uncertainty around 
the chance of response success (only for 
decision makers)
Orthogonal array from SPSS and 
Shifted Design technique.  MNL 
and mixed logit (MXL)
For both samples, increased survival, QOL and 
chance of response success, and a reduction in cost 
and uncertainty (decision makers only), increased 
the likehood that a pharmaceutical would be chosen 
for funding. Pharmaceuticals used for the treatment 
of severe disease were also more likely to be funded.
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TABLE 5 – SUMMARY OF THE LITERATURE REVIEW FOR THE DCE IN PHAMACEUTICAL FUNDNG DECISIONS
Study/coun-
try
Study focus Attributes
Study design and estimation 
method
Key findings and conclusions
Public Preferences
Whtty et al. 
2008. Australia
Public preferences for allo-
cation resources for phar-
maceuticals 
Chance of success, Survival, Quality of 
life, Additional cost
Fractional factorial additive main 
effects design obtained from 
SPSS. Multinominal logit (MNL) 
model.
Public consider  QoL after treatment, survival after 
treatment and chance of success of  a new pharma-
ceutical  important attributes when funding pharma-
ceuticals for the treatment of others suffering a severe 
illness.
Decision Makers/Health Professionals Preferences
Diaby et al, 
2011. Canada
Preferences of physicians 
in Côte d’Ivoire when se-
lecting reimbursable phar-
maceuticals
Cost effectiveness of treatments, severity 
of the disease, age and social class
Optimal design for proposed by 
Street et al, 2005. Binary logistic 
regression, STATA 8.0
Preferences of physicians in Côte d’Ivoire are based 
on cost effectiveness, severity of disease, and social 
class.
W. Linley, D. 
Hughes, 2013. 
UK
Preferences of All Wales 
Medicines Strategy Group 
(AWMSG) appraisal com-
mittee and appraisal 
sub-committee (New Med-
icines Group) members 
(‘appraisal committees’) 
for specific new medicines 
adoption criteria
Main impact of disease before treat-
ment, annual number of patients to 
be treated, QALYs gained per treat-
ed patient, incremental cost per 
QALY gained, uncertainty in cost 
effectiveness is thoroughly explored 
Fractional factorial de-
sign, we therefore used an 
orthogonal main effects plan 
from Shaphira’s catalogue, 1996. 
Conditional logit, main effects 
only, STATA10.1
A willingness to trade the cost effectiveness and QALY 
gains against other factors indicates that economic 
efficiency and QALY maximisation are not the only 
considerations of committee members when making 
recommendations on the use of medicines in Wales
Public Vs. Decision Makers Preferences
Whitty et al. 
(2011) Aus-
tralia
Evaluate the consistency of 
public and decision maher 
preferences for the publc 
subsidy of pharmaceuticals
Chance of response success, survival, 
quality of life (QoL), cost to government 
per person treated. Uncertainty around 
the chance of response success (only for 
decision makers)
Orthogonal array from SPSS and 
Shifted Design technique.  MNL 
and mixed logit (MXL)
For both samples, increased survival, QOL and 
chance of response success, and a reduction in cost 
and uncertainty (decision makers only), increased 
the likehood that a pharmaceutical would be chosen 
for funding. Pharmaceuticals used for the treatment 
of severe disease were also more likely to be funded.
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Chapter 4. Method
1.  Identification Of Attributes And Assignment Of Levels
In this section efforts were towards the definition of meaningful attributes, capable 
of defining a new pharmaceutical. These attributes were then decomposed in levels 
and to describe those attributes in manners of levels so that respondents can make 
choices as the levels vary. A preliminary selection of meaningful attributes is present-
ed in Table 6. This choice draws mainly from a portuguese study that defined several 
attributes to develop and validate a new reimbursemnt system for pharamceuticals. 
Through a Delphi technique, Maria et al. (2007), asked a group of experts, mainly 
physicians, to identify which attributes they consider important when granting reim-
bursemnt for a new pharmaceutical.
TABLE 6 – FIRST SET OF ATTRIBUTES SELECTED (Maria et. al (2007)
Dimensions Attributes Levels
Disease
Probaility of causing 
definite incapcity High (>70%), Moderate (50% to 70%), Low (<50%)
Mortality High (>10%), Moderate (5% to 10%), Low (<5%)
Prevalence High (>5%), Moderate (1% to 5%), Low (<1%)
Patient
Share of the expenditure 
with pharmaceuticals 
on the monthly income
High (>10%), Moderate (3% to 10%), Low (<3%)
Monthly salary (MS) High (>5MS), Moderate (2 to 5 MS), Low (<2MS)
Number of chronic 
disease High (>3), Moderate (2 to 3), Low (<2)
Pharma-
ceutical
Efectiveness High (>70%), Moderate (50% to 70%), Low (<50%)
Security High (high Benefit/Risk ratio, Low  (poor Bene-fit/Risk ratio)
Exhisting alternatives Yes, No
The number of attributes to include in the DCE is an important issues to balance. 
When individuals respond to the choices, it is assumed that they are considering all 
the attributes, and making trade-offs among them. It is this assumption that allows 
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such trade-offs to be estimated, and therefore monetary values to be estimated. If too 
many attributes and levels are included, individuals will not consider all the informa-
tion, but adopt simple decision-making strategies (such as always choosing the option 
with the highest pay). If this is the case, estimated trade-offs will not be valid. The 
question is then raised: What is too many attributes? Applications of DCEs in health 
economics have included anywhere between two and 24, with a mode of six (de 
Bekker-Grob et al. 2012). Within the context of pharmaceutical funding the average 
number of attributes is five.
The levels presented in table 6 appear in both quantitative and qualitative scales. 
Although in the questionnare, both ways were presented in the explanatory text, only 
the qualitative scale was carried through th equestionnaire. The main reason for such 
decision was the goal to keep the task simple and not confuse repondents. When 
targeting general public it is important to count with respondent for every educational 
level and ability to comprehend (Champ & Welsh 2006 2006). Table 7 displays the 
attributes and levels assigned for this study. The chosen attributes represented criteria 
that were identified from a review of the literature as likely to be important to the pub-
lic for funding decisions, and which addressed the study purpose (Diaby et al. 2011, 
Maria et al. 2007, Whitty et al. 2008, Whitty et al, 2011). 
TABLE 7 - SELECTED ATTRIBUTES, ITS LEVELS AND SOURCES
Attributes Levels Source
Severity of the disease 
for which the treatments 
are indicated
Not severe
Severe
Very Severe
(Green and Gerard 2009; Koopmanschap, Stolk, 
and Koolman 2010; Maria et al. 2007)
Prevalence of the dis-
ease in Portugal
High
Moderate
Low
(Maria et al. 2007)
Efficacy of the new 
pharmaceutical
High
Moderate
Low
(Diaby et al. 2011, Maria et al. 2007, Whitty et al. 
2008, Whitty et al, 2011).
Government cost (per 
person treated)
500, 1000, 
5000, 
10000, 
50000, 
100000
(Diaby et al. 2011, Maria et al. 2007, Whitty et al. 
2008, Whitty et al, 2011).
Government savings
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1.1. Severity Of The Disease For Which The Treatments Are Indicated
On the literature, severity of a health condition can be defined as the likelihood of 
death or organ failure as a result of disease progression, independent of treatment 
(Mentzakis et al.  2011). Severity of health, the pre-treatment health state of patients, 
is identified in the current literature as a social value that is supported by respondents 
in a number of empirical studies reporting experimental data and in studies reporting 
attitudinal data. Severity of disease is consistently identified as a factor individuals 
consider important for resource allocation in health care (Mentzakis, et al. 2011). The 
quality of life descriptions were drawn from the health state levels of the EQ-5D clas-
sification system corresponding to the Mobility, Usual Activities, and Pain/discomfort 
health states (Dolan 1997). A simplistic scale was adjusted for the questionnaire, 
using “very severe disease”, “severe disease” and “mild disease”. Other things equal, 
we expected that respondents would prefer to fund a drug that treated those with a se-
rious condition than those with a moderate condition. In the questionnaire, examples 
of diseases severity’s classification were used to provide a clear definition of each level 
to respondents (Koopmanschap, Stolk, and Koolman 2010).
Whilst the Portuguese pharmaceutical policy does explicitly consider, the severity of 
the disease for which the treatments are indicated, the different reimbursement rates 
are defined according to the pharmacotherapeutic group. This comprises, indirectly, 
the severity of the disease criteria, assigning higher reimbursement rates for disease 
considered more life threatening. Table 8 presents the attribute and its levels, with an 
inclusion of the example used in the questionnaire.
TABLE 8 – SEVERITY OF THE DISEASE FOR WHICH THE TREATMENT IS INDICATED
Attribute Label QoL score (0-1) Example
Severity of the disease 
for which the treatment 
is indicated
Not severe 0.94 eczema or non chronic, mild low back pain
Moderate 0.65 heart failure or moderate rheumatoid arthritis
Very severe 0.33 progressive multiple scle-rosis
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1.2. Prevalence Of The Disease In Portugal
Frequency of the disease treated by a drug is a primary attribute of interest. Maria, 
2007, showed that the prevalence of the disease is an important attribute to consider 
for the pharmaceutical funding decisions. Drummond et al., 2009 raised some impor-
tant questions on funding medicines for low prevalent diseases. In essence, there is 
a natural tendency to prefer to save the greater amount of individuals, keeping costs 
constant, and therefore to disregard the treatment for low prevalent diseases. The 
efficacy of these medicines is generally poorly stated as it is more difficult to set clin-
ical trials. (Drummond et al. 2009) For these reasons, Drummond (2009), suggests 
that there should be a commitment to a fair decision- making process for drugs for 
rare diseases, recognizing that inevitably this has a value-based foundation. This pro-
cess should, therefore, include appropriate community input, including patients and 
taxpaying citizens. Existing decision-making processes need to be reviewed to assess 
their suitability for dealing with the challenges posed by drugs for rare diseases, in-
cluding some cancers. Promising initiatives, such as attempts to engage stakeholders, 
including patients and the public, or to undertake conditional field evaluations, need 
to be supported and built upon(Drummond et al. 2009). The attribute prevalence of 
the disease was presented to respondents followed by examples, as showed in table 
9. Green (2009), on the conclusion of his study, states that the number of individual 
being treated is a desirable attribute to include while eliciting preferences on social 
issues.
TABLE 9 – PREVALENCE OF THE DISEASE IN PORTUGAL
Attribute Label Percent Example
Prevalence of the 
disease
Low < 1% Renal failure
Moderate Between 1% and 5% Bronchitis, malignant tumour
High >5% Hypertension
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1.3. Efficacy Of The New Pharmaceutical
The standard goal of the Portuguese regulatory agency, INFARMED, is to provide cost-ef-
fective pharmaceuticals and to assure its quality and efficacy. The efficacy of a treatment 
is defined as the probability of the pharmaceutical to produce the expected results. The 
efficacy is a criteria used by INFARMED to determine the therapeutic added value of a new 
pharmaceutical. In the assessment phase, the clinical, pharmacotherapeutic and phar-
macoeconomic outcomes of a pharmaceutical are quantified and compared to available 
reimbursed drugs. The assessment thus determines (incremental) cost-effectiveness ratio 
of a pharmaceutical. In principle, the elements considered in the assessment phase can 
be broader, including also a description of ethical and organisational issues. In order to in-
vestigate if the public considers the same criteria the government does, or if they are willing 
to trade the maximization of efficacy on the outcomes for equitity, this was included in the 
study. The levels were defined according to Maria (2007). Each level was firstly presented 
in the questionnaire on an introductory text, with its description. Table 10 presents the 
levels that describe this attribute.
TABLE 10 – EFFICACY OF THE NEW PHARMACEUTCAL
Attribute Label Percent
Efficacy of the new pharmaceutical
Low < 50%
Moderate Between 50% and 70%
High >70%
1.4. Government Costs/Government Saving
It was decided to frame the cost attribute in terms of government values (Table 11). There 
was little prior guidance in the literature on plausible levels for government costs, so levels 
were chosen to represent a wide range of costs that the public might be likely to associate 
with pharmaceuticals). Initially, we were keen to define the cost attribute as a government 
saving if the reimbursement was not granted to the pharmaceutical. Regarding the Por-
tuguese economic context, it seem more relevant in a policy perspective to present re-
spondents with the possibility of directly choose public savings. The question about if this 
cost attribute wouldn’t compromise the easiness of the task arises. Therefore, on the pilot 
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study, each attribute was tested. Although, the scenario of government cost savings may 
reflect more accurately the Portuguese economic situation, the qualitative pilot test forced 
to chose the attribute government cost per person treated. This issue is further discussed.
TABLE 11 – GOVERNMENT COST PER PERSON TREATED
Attribute Levels
Government costs per person treated 500, 1 000, 5 000, 10 000, 50 000, 100 000
Government costs per person treated was included and allowed us to identify respond-
ents’ views regarding the amount the government should be willing to pay at the mar-
gin for a pharmaceutical. Government costs per person treated took on six levels rang-
ing from €500 to €100,000. A priori expectations were that, ceteris paribus, the lower 
the per-patient cost the higher the probability of choosing that particular alternative. 
2. Experimental Design
Having decided the relevant attributes  levels, hypothetical choices with different combinations of 
attributes and levels were formulated and presented to respondents. The selected attributes and 
levels resulted in 162 profiles (3 attributes with 3 levels and 1 attribute with 6 levels = 3^3 x 6^1), 
and 13041 pairwise choices (162*161/2).  As it is not possible to present respondents with all 
the possible combinations of choices, the experimental design methods are used to reduce 
the numbers of choices for respondents. A fractional main effects design was chosen, where 
statistical efficiency of the design was maximized with orthogonality, level balance and minimal 
overlap. Orthogonality is assumed when there is a linear relationship between all attributes with 
no attribute having a dominant position within the design. An orthogonal experimental design 
was constructed using an orthogonal array from Sloan’s website (Sloan, 2009)  http://www.
research.att.com/~njas/oadir) (Street, Burgess, and Louviere 2005). The orthogonal array was 
a multiple design and included a fractional factorial design with 18 choice sets, 5 attributes each 
at 3 levels and one with 6. Of this array, only four of the columns were used (Appendix A). The 
removal of columns is proven to be an effective approach (Hensher et al. 2005; Street et al. 
2005 and Burgess & Street, 2008). The data was then converted using the levels identified in 
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Appendix C. Following Louviere et al. (2000), a “foldover” method was used to obtain consistent 
pairwise choices.  A foldover design is defined as a systematic level change of the original design 
(0=1, 1=2, 2=3, and 3=0) which results in a design that has a higher efficiency (Street, Burgess, 
and Louviere 2005).  Following this, the design was then tested for level balance acknowledging 
an equal number of levels to be assigned with each of the product attributes. Further, minimal 
overlap was assessed by checking that no attributes had the same level within a choice set. 
Consistent with most applications of DCEs within health economics, only main effects were 
estimates (de Bekker-Grob, 2012). It is argued that such effects explain most of the variation in 
preferences, assuming that nonlinearities and interactions are negligible (Kløjgaard et al 2012; 
Ryan, Watson, & Gerard 2005). An unlabelled, forced-choice experimental design was chosen. 
Hence, for every decision, respondents faced a choice between two pharmaceuticals used to 
treat undefined disease with specified attribute levels for each. 
2.1. Number Of Choices And Cognitive Fatigue
Even after using experimental fractional factorial design methods, a large number of 
choices may remain for presentation to respondents. The design selected resulted in 
eighteen choice sets. This raises the question of the number of choices subjects can 
respond to, before becoming tired, bored, or unmotivated. The number of choice sets 
that respondents are presented with in DCEs in health has increased, with the mean 
number at 14 (de Bekker-Grob et al. 2012).Acknowledging this, a design with 18 choice 
sets seemed plausible.
2.2. Inclusion Of A Validity Test In The Choice Task
The experimental design included one choice sets where one alternative unquestion-
ably dominates the other(s) on all attribute (Appendix I, question 11). We decided to 
keep these questions in order to test the rationality of responses. ‘Incorrect’ responses 
can either be interpreted as a result of irrational respondents, a lack of understanding 
of the choice task, or a simple mistake on the part of the respondent (Kjaer 2005).
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2.3. Checking Properties
Huber and Zwerina (1996), outlined four criteria to consider when constructing a 
survey; namely, orthogonality, level balance, utility balance and minimal overlap. How-
ever, obtaining a balance between the different criteria is a matter of judgment since 
improving some of the criteria can come at the expense of others. The main criteria 
adhered to in this study were orthogonality, level balance and minimal overlap. The 
constructed design allows for this three of the four principle of an efficient design, as 
shown in table in appendix B, table 17.
3. Data Collection
3.1. The Questionnaire
After obtaining the optimal experimental design, the task of constructing the survey in-
strument then moved on to designing the layout and overall presentation of the survey. 
Each survey contained a title page explaining to the respondents that the data was be-
ing collected as part of a postgraduate research project, was confidential, and would 
have no impact on actual policy making. The approximate time to complete the study 
was also provided, acknowledging the approximate length of completion. The second 
page included a likert scale, used as the warm-up questions. Here, respondents were 
asked to answer general questions about their view on the Portuguese reimbursement 
system. Page three comprised instructions about the scope and how to face the DCE. 
The purpose of the choice set was explained, stating that we would like to know how 
the respondent prefer to allocate public funds, when it comes to fund pharmaceuti-
cals. We explained the real decision context, stating that the budget for pharmaceuti-
cal funding is limited and there are more drugs available than can be funded with the 
budget, so choices must be made regarding which drugs to fund.  Respondents were 
then asked to imagine the decision was up to them, and to choose which pharmaceu-
tical they prefer, considering all presented attributes. Page four described the selected 
attributes and levels, with tables and examples. Page five included an example of an 
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answered choice set and included the interpretation of such choice. The following pag-
es were the DCE itself. The last section covered demographic, economic and health 
status information the collection of demographic and heath status information about 
the respondent. The questionnaire is divided three parts, being the 1st and the 3rd, 
supporting questions and the second part the DCE itself.
3.1.1. “Warm-Up” Questions: The Likert Scale
Respondents are expected to have different experiences with medicines along with 
a heterogeneous attitude facing the Portuguese reimbursement system. A bunch of 
generalist questions, shaped as a Likert scale, were firstly presented to respondents. 
These were attitude and experience questions, primarily asked to focus the respond-
ent on the issue we study. 
This first part included questions about how well respondents understand the Portu-
guese reimbursement system and generic questions about how the reimbursement 
should be granted (for example, only for people with low income or only for non ex-
pensive medicines).  
Whilst economists have used rating scales to estimate quality weights or benefit 
scores, other social and behavioural scientists have tended to favour scales that are 
concerned with respondent’s attitudes. A common technique used here is the Likert 
scale. This contains a series of opinion statements on a given issue. Respondents’ 
attitudes are elicited by presenting them with a series of statements and asking them 
their level of agreement on an agree–disagree continuous scale. This is often an ‘odd’ 
number scale, with a neutral/undecided point in the middle. 
Methodological evaluations of Likert scales have been limited in healthcare, outside 
of their use in satisfaction studies. The literature states good internal consistency 
and reliability. Construct validity is also supported in terms of convergent validity, 
Likert scales demonstrated good results. A major disadvantage of totalling up scores 
is that “while a set of respondents will always add up to the same score, the same 
total may arise from many different combinations of responses, which lead to a loss 
of information about the components of the scale score”. Nevertheless, Likert scales 
are relatively easy to complete and seemed a good way to introduce the questionnaire. 
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3.1.2. DCE Section
Respondents faced a dichotomous choice (i.e. choose alternative A or B) as shown in 
Figure 2.
FIGURE 2 - DCE QUESTIONNAIRE (QUESTION TEMPLATE)
1. Please compare the following medicines and select which one you think should BE 
REIMBURSED:
MEDICINE A MEDICINE B
Severity of the disease Very severe Not severe
Prevalence of the disease Moderate Low
Medicine’s efficacy Low efficacy Moderate
Government costs 10 000€ 5 000€
Medicine A Medicine B
Please tick one box: o o
3.1.3. Socio-Demographic Questions
It is desirable to include some questions on socio-demographic variables (Champ, 
2006). The inclusion of socio-demographic questions makes it possible for the re-
searcher to split the sample into subgroups and to test whether different groups of 
respondents answer differently, e.g. to test for heterogeneity in preferences. In prac-
tice this is done by examining interactions between personal characteristics and the 
desired attributes (Kjaer 2005).  Age, gender, qualifications, health status, profes-
sional status, income, monthly expenditure with medicines, private health insurance, 
benefits from any reimbursement subsystem or reimbursement special scheme were 
included. 
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3.2. Qualitative Work: Piloting
This study targets the general population, with a random sample of citiziens. There-
fore it is important to assure that every respondent who could probably receive the 
questionnaire would understand the task and be willing to perform it. Regarding this, 
qualitative work was developed.
For a DCE, qualitative work can take many forms. Taking in account the context of this 
work, namely the time and budget available, a small pilot was conducted, with eight 
respondents. 
Many reasons motivated the pilot: detecting possible errors and amending them be-
fore the main study, clarifying if the attributes are meaningful for respondents, identify 
any misunderstanding that could arise from the terminology used, evaluating the level 
of comprehension and difficulty of the proposed task, determining how long respond-
ents take to complete the questionnaire. 
The pilot consisted of asking the selected individuals to answer the questionnaire 
following a think aloud methodology. The respondents were recorded, with a cam-
era, while they were answering the questionnaire. Before this, respondents signed 
an informed consent and were showed a template video to illustrate the think aloud 
method. This procedure was followed by careful analyses of the videos. Each video 
was seen in the day the task was performed. Amendments to the questionnaire were 
due at the end of each pilot and results are showed in table 13, page 53.
Think aloud data can be obtained in two ways: concurrent and retrospective. Concur-
rent think aloud asks respondents to verbalise their thoughts as they complete a task. 
Retrospective think aloud asks respondents to describe what they were thinking after 
the task has been completed.  We used a concurrent think aloud method. Respond-
ents were asked not to explain or plan what they were saying, but to act as if they were 
speaking to themselves.  There is still some uncertainty around how individuals make 
their choices which may emphasize the need of planning qualitative work such as a 
verbal protocol. However, there is evidence that individuals use simplifying heuristics 
when faced with complex decisions, and that preferences may be constructed at the 
time rather than existing previous to the task. Individuals may also be unwilling to 
trade, making choices based on a single high priority attribute. It is not clear whether 
behaviour which does not correspond to the assumptions underlying economic theory 
reflects limitations in the decision maker or task- related demand characteristics. 
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3.2.1. Tested Features
A) Opt-Out Question
The pilot showed evidence on propensity for choosing the opt-out alternative. While 
performing the DCE, one respondent verbalized the will to choose none. The rea-
soning behind this was that so sensible from an ethical point of view that they would 
rather not make the choices at all. Since that the respondent did not avoid the task 
because he felt none of the options were plausible, but rather because he didn’t felt 
comfortable on having to choose one pharmaceutical over other, we decided to keep 
the questionnaire as a forced task. There evidence that, when faced with sensitive 
hypothetical decisions, there is a trend of respondents to avoid answering.
B) Cost attribute
One important aim of the pilot was to investigate the best way to present the cost 
attribute to respondents. Table 12 highlights the framed question for each version and 
the number of respondents for each version.
Reactions to version 0, where the cost attribute was presented as government savings, 
revealed difficulty in understanding the question which resulted in 2 incoherent an-
swers (respondents verbalized their answer as if the cost attribute was “government 
costs per person treated”). Another respondent had to go back several times to the 
introductory page where the cost attribute was described. After these pilot results, 
that denoted confusing over understanding the cost attribute when framed as “govern-
ment savings”, only version 1 was used to complete the qualitative work.
TABLE 12 – DIFFERNCE BETWEEN TWO VERSIONS OF THE QUESTIONNAIRE
Version 0 Version 1
Code P 00X P 01Y
Question Which of the following medi-
cines you think should not be 
reimbursed?
Which of the following medi-
cines you think should be re-
imbursed?
Cost attribute Government cost saving Government costs per person 
tretated
Number of respondents 3 5
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TABLE 13 – PILOT RESULTS
Pilot 
Num-
ber
Pilot 
Ver-
sion
Amendment Section Respondent Reaction/Quote
1 0
Include the option “ no 
monthly expenditure with 
pharmaceuticals”
 Demograph-
ics
“I don´t have any expendi-
tures in pharmaceuticals”
1 0
Change the question from 
“Which health subsystem 
do you benefit from ”Do 
you have any health sub-
system”
Demographics
Respondent seemed con-
fused with the options avail-
able
C) The Likert Scale
Respondents reacted positively to the Likert Scale task. The think aloud method was 
the key for the researcher to understanding how respondents face the Portuguese 
funding pharmaceuticals. On distributive questions, respondents found interesting the 
set of questions presented, stating that they have never thought about these prob-
lems. Respondents took a fair time thinking and raising equity and ethical questions 
while responding. The Likert scale is presented in Appendix F.
D) Levels
Generally the respondents found the levels feasible and with an acceptable range, 
forcing them to make decisions. Respondents didn’t seem confused about the pre-
sented levels nor about the way they were explained.
E) Framing
Although all respondents expressed that the framing of the questionnaire was clear 
and concise, the qualitative test resulted in some amendments on the framing (Table 
13). They readily started to fill the questionnaire, just based on the provided instruc-
tions, and with no questions. At first, respondents were suprised of having to choose 
to fund one treatment over another. Most respondents have never realized this were 
actual choices and would prefer not to chose, or reimburse all the medicines.
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One respondent was reluctant to complete the DCE, stating that it was not fair to do 
such decisions. There was the need to explain the task and emphasize that although 
she was facing hypothetical scenarios, the choice involved in the decision reflected 
real choices done by decision makers when facing limited public budgets. 
F) Attributes
All the respondents agreed that the chosen attributes reflected their concerns about 
the reimbursement of pharmaceuticals and that the questionnaire presented an easy 
task. However, through the analyses of the think loud records, we concluded that there 
were some obstacles to the conclusion of the questionnaires. This statement will be 
clarified through this section. Overall, the proposed design proved to be well accepted 
by the respondents. There was some confusing when the cost attribute was presented 
as government savings so this version was dropped before the main study. 
3.2.2. Conclusions From The Pilot
The qualitative data from the verbal protocol analysis is a powerful tool that has been 
exploited to test response motivations in stated preference studies. Although in this 
study we just used it to provide information about the structure, design and terminolo-
gy of the questionnaire, it can provide rich information about respondents’ preferenc-
es. Ryan et al., 2009, used a verbal protocol analyses combined with a DCE to test if 
2 0 Shorten the description by simplifying it
DCE
(instructions)
Skipped the description of 
economic evaluation
2 0 Remove example from the question Lickert scale
“smokers shouldn´t benefit 
from co-payments? Why pe-
nalize them? What about the 
individuals  who have other 
unhealthy habits? 
3 0 Remove double word “studying” Demographics -
1 1
Question 14, cost value 
changed from 50 000€ to 
5 000€
DCE -
TABLE 13 – PILOT RESULTS (CONT)
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respondents hold complete, monotonic, and continuous preferences and why some 
people fail standard applied quantitative test (Ryan te al. 2009). 
Overall, the proposed design proved to be well accepted by the respondents. There 
was some confusing when the cost attribute was presented as government savings so 
this version did not followed to the main study. 
3.3. Sample Design And Data Collection Method
Most of DCE applied to the health care market target a specific group of  population 
such as patients, decision makers or health care practitioners (de Bekker-Grob et al. 
2012). Due to the nature of the present study, it was decided to focus on the general 
population. Rather than elicit preferences for a defined pharmaceutical or for a given 
disease, this study covers the problem of public funding of pharmaceuticals, through 
the point of view of tax payer. This is in line with the shape of the cost attribute, which 
will, ultimately, allow us to conclude if there the public is a concern about how much 
should the government pay for health, and, more specifically, for pharmaceuticals.
The survey was administered to a probability sample, on the geographical area of São 
Vitor which in the Portuguese city of Braga. The parish has an estimated population 
of 29.642 inhabitants (Census, 2011) thus requiring a sample of 377 individuals, in 
order to be representative (95% confidence level and 5% and a confidence interval of 
5%) (sample size obtained through online calculator: http://www.raosoft.com/ sam-
plesize.html).
The parish was selected for being the biggest parish on the city and because it com-
prises a very heterogeneous population and a wide geographical area. 
The aim is to obtain a probability sample, giving more value to statistical inference. To 
do so, there were made contacts with the post office to obtain the best service. The 
first idea was to determine the geographical limits (the ones of the referred parish) 
and they would distribute the surveys in random base. The only service the post office 
offers to do so, does not allow to get a record of the addresses. This was not conven-
ient for our study as we aimed to send more than one correspondence.
A database with 218 streets was introduced into Excel®, 2007, and subsequently 
randomized till 40 streets were left. In each street, 10 questionnaires were delivered, 
resulting in 400 questionnaires. 
Randomisation within an experimental design is a way of ensuring control over con-
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founding variables and as such it allows the researcher to have greater confidence in 
identifying real associations between an independent variable (a potential cause or 
predictor) and a dependent variable (the effect or outcome measure). 
The complete questionnaire is in appendix I. The advantages of paper surveys include 
the ability of respondents to complete the survey at their convenience and at their 
own pace. Respondents may also feel more comfortable offering honest respons-
es to sensitive questions if they are not facing an interviewer while completing the 
questionnaire. The downside of paper surveys is the lack of control over the order in 
which the respondent answers the questions. Further, f the respondent doesn’t have 
contact with the research, doubts about the questionnaire may arise while completing 
it, remaining unclear.
During 26th and 27th May, 400 questionnaires were administered through mail in S. 
Vitor’s area. The envelope contained the main questionnaire, one post card, present-
ing the study and a response free of charge envelop.
After one week, a remembering post card (annex B) was delivered on the same ad-
dresses, thanking the response, if already done, or emphasizing the importance of 
replying if not yet done.
The first documentation outlined that we expected responses within two weeks. Nev-
ertheless, few were the responses that got to the post office in time. Therefore, we 
extended the calendar for one month. Responses received after the 27th June were 
not considered.
4. Data Analyses
4.1. Data Input
After the data are collected, they need to be organized and set into a computerized 
database Statistical package STATA 10 ® was used to analyse the data. Each choice 
set contains two forms of information: 1) The attribute levels of each alternative, and 
2) Which of the given alternatives has been chosen. Each attribute level has to be 
coded in order to estimate the importance of each attribute, i.e. the marginal values 
and trade of ratios. The coded data of the choice set and data input, is presented in 
Appendix C. For this task we used a dummy variable coding. Attributes are coded so 
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that the constant term is used to reflect what is expected to be the least desirable 
option (for funding) in the factorial design.
4.2. Econometric Analyses
The DCE was analysed with a conditional logit regression taking each choice among 
the two options (pharmaceutical A and pharmaceutical B) as an observation. Assum-
ing that all attributes have an independent influence on respondents’ preference, the 
following model was estimated:
Where:
 - V represents the utility derived for the new pharmaceutical
 - β0 is a constant reflecting the respondents’ preference for pharmaceutical A 
over pharmaceutical B.
 - β1 to β4 are the coefficients that indicate the relative importance of each 
attribute. 
The signs of the coefficients reflect whether the attribute has a positive or a negative 
effect on utility. The value of a coefficient indicates the relative importance of the 
corresponding attribute. A priori we expected that only the cost attribute would have 
a negative significant coefficient. The trade-offs that the respondents were willing to 
make between the attributes were estimated by the ratios between the coefficients. 
The coefficient of the cost attribute is used to estimate the willingness to pay (WTP).
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Chapter 5. Results And Discussion
1. Response Patterns
400 questionnaires were mailed and 39 of them were returned. Of these 39 respond-
ents, 34 completed the DCE questionnaire, resulting in a response rate of 8.5%. The 
number of individuals providing responses for the regression analysis is 34, providing 
612 choice responses and 1224 observations. 
An additional set of 56 surveys were administered locally, on the headquarters of 
the Parish of São Vítor. These 56 individuals provided 2016 observations from 1008 
choice responses.
In line with the findings of the pilot, it seemed that respondents understood the task 
and faced it as hypothetical scenarios that reflect a real decision. One of the respond-
ents refused to answer writing that he couldn’t decide on such a delicate question and 
that all pharmaceuticals should be funded.
2. Characteristics Of Respondents
Respondents were aged between 18–80 (mean 45.08), 74% were female. 45.05%, 
reported a good health status, while 13.64% declared a bad or very bad health status 
(table 14). The monthly expenditures with pharmaceuticals was reported to be be-
tween 6€ – 25.99€ for 40.7% of respondents and between 26€ and 50.99€ for 22.1% 
of respondents. Only 4% of the respondents have commissioned a private health in-
surance and 5.9% benefit for an additional reimbursement scheme, due to specific 
diseases. 
Individuals in the non-random sample have, on average, a lower income and lower 
educational level than the random sample. Further, the non random sample has 30 
% of individuals away from work ill, while none of the respondents from the random 
sample reported to be in this situation. 
In order to test that both samples were equally distributed in terms of socio demo-
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graphic characteristics, a chi-squared test was performed to compare them. The results 
showed that there is significant difference in some variables, namely income, education 
level and professional situation, at conventional levels (Appendice G). The results are, 
therefore, reported separately.
It is important to underline that this study was not intended to be representative of the 
Portuguese population. Nonetheless, we find of relevance to contextualize our sample in 
the pattern of the Portuguese population. Comparing to the Portuguese population (Cen-
sus 2011), both samples are more likely to have female respondents. Further, high ed-
ucated individuals are overrepresented comparing to the Portuguese population (15%). 
Most respondents (45.4%) state that they have a good health status. Only 25% reported 
one chronic disease while the statistic for the Portuguese population is 40.5%.
TABLE 14 - RESPONDENTS’ CHARACTERISTICS
Category Random sample
Non random 
sample Ch2
Age (mean) 47.3 43.4 0.2731
Gender (%) Female 63.64 80.7 0.079
Education (%)
Higher education 69.7 32
0.009
Secondary education 21.21 36
Basic education 3 24
Primary education 3 6
Never studied 3 2
Rather don’t say 0 0
Health status (%)
Very good 21.21 8.93
0.178
Good 51.52 42.86
Fair 21.21 30.36
Bad 6 10.71
Very bad 0 7.14
Chronic diseases (%)
No 66.67 66.07
0.375Yes, one 30.3 23.21
More than one 3 10.71
Employment (%)
Unemployed 0 30.36
0.004
Retired 27.27 30.36
Working 54.55 50
Studying 6.06 1.76
Disabled 3.03 1.79
Away from work ill 6.06 8.93
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TABLE 14 (CONT) - RESPONDENTS’ CHARACTERISTICS
Category Random sample
Non random 
sample Chi2
Income (%)
None 15.15 21.43
0.039
Up to 485.99€] 3.03 12.5
[486€ ;900,99€] 21.21 30.36
[901€;1455,99€] 24.24 12.5
[1456€;1940,99€] 9.09 7.14
[1941€;2425,99€] 15.15 8.93
[2426€;3395,99€] 12.12 0
More than 3396 0 0
Rather not say 0 7.14
Monthly expenditure 
with pharmaceuticals 
(%)
None 8.82 9.62
0.971
Up to 5.99 11.76 7.69
[6€ ;25,99€] 38.24 42.31
[26€; 50,99€] 20.54 23.08
[51€;75,99€] 5.88 3.85
[76€;100,99€] 5.88 7.69
[101€; 150,99€ 0 0
More than 151€ 5.88 1.92
Don’t know 2.94 3.85
Benefits from special 
scheme of reim-
bursement (%)
Yes 2.94 3.92
0.414No 88.24 96.08
I don’t know 2.94 0
Private health insur-
ance (%)
Yes 8.82 1.79
0.116
No 91.18 98.21
3. Model estimation and interpretation
The individuals were asked to choose between two alternatives (pharmaceutical A and 
pharmaceutical B). 
Two of the respondents answers failed a ‘consistency check’ question, choosing the 
option that was dominated across all attributes by the alternative available and a 
third provided  answers in a “geometric pattern”.  Therefore, in 8.8% of cases (3/34) 
the sample did not meet the requirement for consistent answers. Given the societal 
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context of the survey (Green and Gerard 2009), and a lack of clarity in the research 
literature on what might be classified as irrational response data (Lanscar and Lou-
viere, 2006; Ryan et al 2009), the data from these respondents was included in the 
analysis. 
As described on the method, the sample design resulted in two different groups of 
the same population, one selected randomly and the other handed personally. On 
both methods, as showed in appendix D, a random selection of the respondents was 
motivated by the request that one resident of the house, aged over 18 years old and 
whose birthday is closest to the current date, to respond to the questionnaire. The 
likelihood-ratio test (LR chi2(7)= 38.58; Prob > chi2 = 0.0000) reject the null hypoth-
esis, that stated preferences are the same when samples are analyse as a whole or 
separately.  Therefore the samples were reported separately. Table 15 reports the 
results of the conditional logit model, for analysis of main effects on both samples.
TABLE 15 – RESUTS FROM CONDITIONAL LOGIT MODEL FOR EACH RANDOM AND NON RAMDOM SAMPLES
Samples Random Non random Whole sample
Results
Very severe 
(p value)
2.045199 
(0.0001)
1.35059
(0.0001)
1.527974
(0.0001)
Severe 
(p value)
1.299507
(0.0001)
0.8244396
(0.0001)
0.9322099
(0.0001)
High prevalence 
(p value)
1.929115
(0.0001)
1.093388
(0.0001)
1.27659
(0.0001)
Moderate prevalence 
(p value)
2.035019
(0.0001)
1.184279
(0.0001)
1.368776
(0.0001)
1Very effective 
(p value)
2.645672
(0.0001)
1.253538
(0.0001)
1.621912
(0.0001)
Moderate effectiveness 
(p value)
1.68076
(0.0001)
0.893373
(0.0001)
1.10018
Government costs per person treated 
(p value)
-0.0000127
(0.0001)
-0.00000389
(0.010)
-0.000005.88
(0.0001)
Log_likelihood (intercept only) -220.20122 -515.14322 -754.63669
Chi-squared statistic 408.01 367.1 736.52
Adj Mc Fadden’s R2 0.4809    0.2627 0.3280
Number of individuals 34 56 90
Number of observations 1224 2016 3240
Likelihood ratio test:
LR chi2(7)
Prob > chi2
37.56
0.00001
-
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4. Model Fit
The pseudo R2, after adjustment for the degrees of freedom, was 48% for the random 
sample and 26% for the non random sample, indicating an acceptable fit for both 
models (Table 15) (Hensher et al., 2005). Furthermore, the models returned a high 
chi-squared statistic, 408.01 for the random and 367.1 for the non random sample, 
indicating that the estimated model has improved explanatory power over a model 
where only constant terms were included. 
5. Importance Of Attributes
Table 15 presents the results from conditional logit model. As showed, all attributes 
were statistically significant at the level of 1% (alpha ≤0.01). Also, both samples report-
ed a negative and significant coefficient for the government cost per person treated 
attribute, showing that respondents prefer these attribute to take lower levels. In other 
words, respondents showed that, other things equal, they prefer the government to 
fund less costly pharmaceuticals. The results were in line with expectations and pro-
vided support for the theoretical validity of the model. The attributes “very severe” 
and “very effective” had high and positive coefficients on each sample, although with 
different ranks of priority. This reflects that, status quo, respondents prefer the gov-
ernment to fund a pharmaceutical to treat a serious condition rather than a moderate 
condition, and a pharmaceutical with high efficacy. These results were expected and 
in line with previous studies (Diaby, et al. 2011, Whitty et al. 2011, Whitty et al. 2008). 
For the random sample, the regression coefficients indicated that “severity of the 
disease for which the treatment is indicated” had the strongest influence on respond-
ent’s choice behaviour, followed by efficacy of the pharmaceutical, prevalence of the 
disease and government costs per person treated. On the other sample, effectiveness 
of the pharmaceuticals had the higher positive coefficient, indicating that, for these 
respondents, a pharmaceutical with high efficacy seems to be the most important 
attribute for funding decisions. In this group, efficacy of the new pharmaceutical is 
followed by the severity of the disease for which the treatment is indicated and prev-
alence of the disease ranks as the least relevant attribute, although still significant. 
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Unexpectedly, the coefficient for moderate prevalence of the disease is higher than 
for high prevalence of the disease. Individuals may have showed concerns about 
distributional and equity principles, preferring pharmaceutical that may, ultimately be 
associated with a more rare disease. Also, respondents may have related the attribute 
prevalence of the disease with the attribute government costs per person treated, 
which may conduct them to choose a less prevalent disease in order to save public 
funds. Nevertheless, this result was not accounted while designing the experiment as 
the qualitative pilot did not revealed such potential relation. This issue requires further 
research, namely a depth qualitative work.
6. Socio Demographics Interactions
An interesting approach that the DCE methods is the investigation of the relation 
between the socio-demographics characteristics of the respondents and the utility 
they assign to each attribute by choosing an alternative. To allow for variation in pref-
erences (therefore WTP values), interaction terms were created between the attributes 
and characteristics of respondents to test its ability to influence preferences. The 
whole sample was used for this estimation (table 15). The subgroups were defined a 
priori based on a review of the DCE literature. Income is assumed to change the way 
respondents weigh the cost attribute and the self-reported health status to influence 
the way they valuated the severity of the disease for which the treatment is indicated 
attribute (Green and Gerard, 2009). Nonetheless it is important to emphasize that, as 
the cost attribute in our study is framed as public costs, such relation wasn’t expected, 
or at least it wasn’t expected to be notorious. The results (chi2 (6) = 1.87 and  Prob 
> chi2 = 0.931)  show that income levels are not  associated with the willingness to 
accept the government to fund pharmaceuticals.
Further, the hypothesis that respondents with a worse self reported health status 
would input increasing marginal utility on a pharmaceutical which is indicated to treat 
a very severe disease was tested. Contrary to what we expected, the result - chi2(  4) = 
6.69 and Prob > chi2 =  0.1530 – did not allow to conclude that the reported health 
status influences the choice. This may be related to the small size of the sample and 
to the overrepresented individuals that reported a good health status.
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7. Marginal Willingness To Pay
The inclusion of a cost attribute is useful for the calculation of the marginal willingness 
to pay (MWTP) respondents indirectly showed through the task. The results for WTP 
and MWTP are presented in table 16.
Although we are not considering out-of-pocket money as the paying vehicle, the WTP 
was estimated in order to assess respondents’ way of dealing with public funds.
On the random sample, everything else equal, respondents were willing to accept a 
public paying of 161 039€ for a pharmaceutical indicated for a very severe disease. 
The marginal willingness to pay (WTP) for a pharmaceutical indicated for a very severe 
disease, rather than for a pharmaceutical indicated for a moderate severe disease is 
58.716€.
The non random sample indicated, everything else equal, that the respondents will-
ingness to pay more, 347 195€ in terms of public funds for a pharmaceutical indi-
cated for a very severe disease. The marginal willingness to pay was 135 257€ for a 
pharmaceutical indicated for a very rather than for a pharmaceutical indicated for a 
moderate severe disease.
On average, the marginal willingness to pay for a very effective pharmaceutical rather 
for a pharmaceutical with moderate effectiveness is 75 977€ for the random sample 
and 91 814€ for the non random sample.
TABLE 16 – WTP AND MWTP FOR EACH ATTRIBUTE
Samples Random Non random
WTP(€) MWTP (€) WTP(€) MWTP (€)
Very severe (β
1
) 161 039
58 716
347 195
135 257
Severe (β
2
) 102 323 211 938
High prevalence (β
3
) 151 899
-8 339
281 077
-23 365
Moderate prevalence (β
4
) 160 238 304 442
Very effective (β
5
) 20 8321
75 977
322 246
92 587
Moderate effectiveness (β
6)
) 13 2343 229 659
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8. Interpreting The Choice Probability
At the level of the scenarios, perhaps a more policy-relevant perspective, it is impor-
tant to consider how the data presented can be interpreted in terms of the relative 
desirability (attractiveness) of the alternative scenarios. The probability scale allows in-
terpretation with ratio-level properties, and allows a judgment against a cardinal scale, 
indicating how much better or worse one option is, when compared with another. That 
is, when comparing estimates of the probabilities that each option will be chosen, it is 
possible to state how much worse (or better) one probability is compared with another 
(Green and Gerard, 2009)
Calculating the choice probability of selected scenarios is a useful tool to inform policy 
makers. This technique is able to turn the results of the regression model into a com-
parative analyse of two scenarios. It is therefore possible to support policy decisions, 
knowing which scenario is more likely to fit respondents’ choice, over another. Taking 
equation 4 in chapter three, the probability of choosing between a set of scenarios 
was calculated. The results are presented in Appendix H. These probabilities provide 
a measure of preference, with higher probabilities (for funding the described scenario) 
showing which scenario is given higher priority (preference) compared with those with 
a lower probability of being chosen for funding (from the full set of scenarios available) 
(Whitty et al., 2008).
The attributes “severity of the disease for which the treatment is indicated” and “effi-
cacy of the new pharmaceutical” had the strongest influence on respondents’ choice 
behaviour on the random and non random sample, respectively. Therefore, this at-
tributes were varied for both the pilot and main study models to provide an example 
of how the models can be used to estimate the probability of a respondents’ choice 
to fund a hypothetical pharmaceutical. In the first hypothetical choice set, holding all 
attributes at their lowest level, except “severity of the disease for which the treatment 
is indicated”, the probability the public would want a pharmaceutical to treat such 
severe disease was 89% for the random sample model and 79% for the non random 
sample model, when compared to a pharmaceutical indicated for a mild disease (for 
which the funding probabilities are 11% and 21% respectively) (Appendix H, table 
19). In the second hypothetical choice set, we find that setting all other attributes to 
their best level compensates significantly for a low “severity of the disease for which 
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the treatment is indicated” level in both models, taking the funding probability for a 
pharmaceutical indicatedfor a mild disease to 75% in the random sample model (from 
11%) and to 65% in the main study model (from 21%) (Appendix H). The same exercise 
was done for the attribute efficacy of the new pharmaceutical.
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Chapter 6: Conclusion
This is the first DCE in Portugal extending the discussion of prioritization in the health 
care sector, namely on the pharmaceutical funding decision, to the general popu-
lation. Whilst this study was undertaken in the Portuguese context and has deep 
exploratory nature, we found consistency between our findings and those comparable 
studies undertaken in the UK, Australia and Canada (Diaby et al. 2011, Whitty et al., 
2008, Tappenden et al., 2007).
This experiment is useful to introduce a new approach to Portuguese policies design. 
It shows the potencial of DCE to inform both marketers in which way to address new 
products and public policy-makers to target resources towards services which are 
likely to give the greatest overall societal benefit (Whitty, 2008).  
In line with other DCEs, this study supports the existence of equity versus efficiency 
trade-off as other studies (Green and Gerard 2009, Whitty, 2008, Diaby, et al. 2011) 
also report. The results suggest that, when considering resource allocation for the 
treatment of others with pharmaceuticals, the public value the efficacy of the pharma-
ceutical, the severity of the disease for which it is indicated, and the prevalence of the 
disease.  This is, to some extent, consistent with the prioritization criteria INFARMED 
uses. The first funding decision consideres the therapeutic value and the economic 
profile of the new pharmaceutical. Further, the law accounts for vulnerable gorups, to 
assign different rate of financing (Chapter 2). 
Additionally, the findings suggest that cost is of relatively little importance when com-
pared to the other attributes. However, it is not irrelevant, and it appears that the 
public are willing to trade between cost and effectiveness, even when the costs are 
publicly supported. In other others, and in line with Whitty (2008), they do not expect 
the government to purchase health gain at any cost. (Whitty et al. 2008). Findings sug-
gest that general public concerns to be both sided, balancing equity principles such 
as severity and prevalence with efficacy and costs, as all attributes were significant 
(Green and Gerard 2009). 
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Respondents from the pilot showed some reluctances in answering the DCE choices 
which suggests that they engaged with the choice task and its context and highlights 
their ability to weigh up the difficult choices presented, offering some confidence in 
the validity of the experiment (Green and Gerard 2009). Further, one respondent from 
the main questionnaire wrote that he noted the relevance of the study and would like 
it to be published in order to be informed of the results.
This study has some limitations that we assume fair considering its explorative nature. 
We identify two main constraints, the budget and scheduled time, to be the main 
sources of limitations. 
Firstly, altough the importance of the qualitative work on a DCE has been aknowledge 
during the work, it was not possible to perform the ideal amount of it. Further qualita-
tive work would have been beneficial for a more grounded selection of the attributes 
and its levels and for the consitency of the results (Klojgard 2012).
Secondly, the sample carries some limitations. The findings of this DCE may be limit-
ed by the sample design, which resulted in a low response rate (8.5%). A small sample 
doesn’t seem to allow the accurate estimation of the interactions between socio-de-
mographic characteristics of respondents and their choices. Besides, the sample is 
not representative of the selected population. Future research may be able to address 
this limitation, with face to face questionnaires to increase response rate and identify 
response errors (Whitty et al., 2008). It is also possible to send an additional post card 
or to reapeat the administration of the questionnaires, in order to incite individuals to 
respond to the mailed questionnaire. 
Expecting such low response rate while designing the DCE, we decided to include an 
additional sample, which aimed to strengthen the main sample and give robustness 
to the results. However, the statistical analyses forced us to consider the samples 
separately which has limited the statistical efficiency of the model ( as it resulted in 
two smaller samples). It may have been useful to design the study differently, e.g. 
using the non-random sample as a pilot sample and the random sample as the main 
study sample. Such study would require more time. Despite these limitations, the 
considerable similarities (in terms of coefficient significance, size and order of attrib-
ute importance) between the models for both samples, suggest that the findings are 
robust (Whitty et al., 2008). 
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The use of the conditional logistic model may be considered a limitation for its simplic-
ity (Green and Gerard 2009). Altough this factor is able to make the findings policy-rel-
evant and the presentation of findings policy friendly it represents potential limitations 
in the methodology. Nervertheless, these preliminary findings can be used to inform 
more detailed future study designs (Green and Gerard 2009).
This research suggests that the results are useful and indicative of what may be pos-
sible in future, through more comprehensive research. The results allow concluding 
that the public is willing and able to provide preferences to inform policy for pharma-
ceutical decision-making, setting foundations for further research.
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Appendix A
 
Figure 3. The mixed-level orthogonal main effects plan MA 18.3.6.6.1 for the multino-
mial design, (Sloan, 2009)
Inside the dashed line box are the columns used for the experimental design
 A1 A2 A3 A4 A5 A6 A7
Choice 1 0 0 0 0 0 0 0
Choice 2 0 1 2 2 0 1 1
Choice 3 0 2 1 2 1 0 2
Choice 4 0 1 1 0 2 2 3
Choice 5 0 2 0 1 2 1 4
Choice 6 0 0 2 1 1 2 5
Choice 7 1 1 1 1 1 1 0
Choice 8 1 2 0 0 1 2 1
Choice 9 1 0 2 0 2 1 2
Choice 10 1 2 2 1 0 0 3
Choice 11 1 0 1 2 0 2 4
Choice 12 1 1 0 2 2 0 5
Choice 13 2 2 2 2 2 2 0
Choice 14 2 0 1 1 2 0 1
Choice 15 2 1 0 1 0 2 2
Choice 16 2 0 0 2 1 1 3
Choice 17 2 1 2 0 1 0 4
Choice 18 2 2 1 0 0 1 5
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TABLE 17 – EXPERIMETAL DESIGN RESULT
C
ho
ic
e MEDICINE A MEDICINE B
Severity Preva-lence Efficacy
Cost 
(€) Severity
Preva-
lence Efficacy Cost (€)
1 Not severe High Low 100000 Severe Moderate Moderate 50000
2 Very severe High Moderate 50000 Not Severe Low High 10000
3 Very severe Moderate Low 10000 Not severe Low Moderate 5000
4 Not severe Low High 5000 Severe Moderate Low 1 000
5 Severe Low Moderate 1000 Very severe Moderate High 500
6 Severe Moderate High 500 Very severe Moderate High 100000
7 Severe Moderate Moderate 100000 Very severe Low High 50000
8 Not severe Moderate Moderate 50000 Severe Low Low 10000
9 Not severe Low Moderate 10000 Severe High High 5000
10 Severe High Low 5000 Very severe Moderate Moderate 1000
11 Very severe High High 1000 Not severe Moderate Low 500
12 Very severe Low Low 500 Not severe High Moderate 100000
13 Very severe Low High 100000 Not severe High Moderate 50000
14 Severe Low Low 50000 Very severe High Moderate 10000
15 Severe High High 10000 Very severe Moderate Low 5000
16 Very severe Moderate Moderate 5000 Not severe Low High 1000
17 Not severe Moderate Moderate 1000 Severe Low High 500
18 Not severe High Low 500 Severe Moderate Moderate 100000
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TABLE 18 – CODING ATTRIBUTES
Attributes Levels
Discription Code Discription CODE
Severity of the disease for which the 
treatment is indicated
A1 mild severe 0
severe 1
very severe 2
Prevalence A2 high
 
0
moderate
 
1
low
 
2
Efficacy of the medicine A3 low
 
0
moderate
 
1
high
 
2
Government costs A4 100 000 0
50 000 1
10 000 2
5 000 3
1 000 4
500 5
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Dear household,
Are you willing to help with research conducted at the University of Minho? 
Within the scope of the Masters in Health Economics and Policy, it is our aim to 
study which criteria d you find important to decide pharmaceutical funding by 
the government.
We therefore ask that one resident of this house, aged over 18 years old and 
whose birthday is closest to the current date, to respond to this questionnaire. 
Such task will takes, approximately, 20 minutes.
The information collected is confidential and it won’t be available for any other 
organization. This means you won’t be identified by your answers.
Your participation is crucial for the success of this research.
We understand that your time is valuable and therefore, we are deeply thankful 
for you cooperation.
FIGURE 4. TEMPLATE OF INTRODUCTORY POST CARD (TRANSLATED)
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FIGURE 5. TEMPLATE OF REMEMBERING POST CARD (TRANSLATED)
Public Stated Preferences for pharmaceutical funding decisions
About 1 week you were sent a questionnaire seeking your opinion about public 
funding of pharmaceuticals.
If you have already completed and returned the questionnaire to us, please ac-
cept our sincere thanks.
If you haven’t yet replied, we very much look forward to receiving your views. If 
you did not receive a questionnaire or it was misplaced, please contact Magda 
Aguiar: pg19509@alunos.uminho.pt or Paula Benesch: 253 604 549 for a re-
placement questionnaire.
Thank you for your help!
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FIGURE 6. 1ST SECTION OF THE QUESTIONNAIRE - WARM-UP QUESTIONS
Part 1. The Portuguese reimbursement system - In this section we want to know what do you 
think about the Portuguese reimbursement system for pharmaceuticals. There are no right 
and wrong answers, is your opinion that counts for us!
Please select (), in each row, one option:
Totally 
disagree Disagree
Uncer-
tain Agree
Totally 
agree
I understand the Portuguese reim-
bursement system for pharmaceu-
ticals
o o o o o
The Portuguese reimbursement 
system for pharmaceuticals should 
simpler
o o o o o
Only the most effective pharmaceuti-
cals should be reimbursed o o o o o
The government spends too much 
money on the reimbursement of 
pharmaceuticals
o o o o o
Only the cheaper pharmaceuticals 
should be reimbursed o o o o o
The reimbursement of pharmaceuti-
cals should be granted just for those 
with lower income
o o o o o
There should be a maximum limit of 
reimbursement per individual o o o o o
Reimbursement rates should be 
calculated based on  the patient 
monthly expenditures  (higher rates 
for those who spend more)
o o o o o
Individuals with unhealthy habits 
shouldn’t benefit from reimburse-
ment
o o o o o
All available medicines should be 
reimbursement o o o o o
Non prescription medicines should 
be reimbursed o o o o o
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FIGURE 7. DISTRIBUTION OF EDUCATIONAL LEVEL (GRAPH1), PROFESSIONAL SITUATION (GRAPH 2 AND 
MONTLHY INCOME (GRAPH 3) FOR EACH SAMPLE.
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APPENDIX H
TABLE 19 – PROBABILITY THAT A RESPONDENT IN RANDOM AND NON RANDOM SAMPLE WOULD CHOOSE 
A HYPOTHTICAL SCENARIO:
RANDOM NON RANDOM
Al
te
rn
at
ie
Se
ve
rit
y
Other attributes 
leves
Sy
st
em
at
ic
 
ut
ilit
y 
(V
)
Pr
ba
bi
lit
y 
of
 
fu
nd
in
g 
(P
r)
Se
ve
rit
y
Other attributes 
leves
Sy
st
em
at
ic
 
ut
ilit
y 
(V
)
Pr
ba
bi
lit
y 
of
 
fu
nd
in
g 
(P
r)
Choice set one
1 High
low prevalence, 
low efficacy, 
100 000€
3.315199 89% High
low prevalence, 
low efficacy, 
100 000€
1.73959 79%
2 Low
low prevalence, 
low efficacy, 
100 000€
1.27 11% Low
low prevalence, 
low efficacy, 
100 000€
0.389 21%
Choice set two
1 High
low prevalence, 
low efficacy, 
100 000€
3.315199 22% High
low prevalence, 
low efficacy, 
100 000€
1.73959 35%
2 Low
High preva-
lence, high 
efficacy, cost 
500€
4.4581137 78% Low
high preva-
lence, high effi-
cacy, 500€
2.348871 65%
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Other attributes 
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ut
ilit
y 
(V
)
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y 
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fu
nd
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g 
(P
r)
Choice set three
1 High
low severity, low 
prevalence, 100 
000€
3.915672 93% High
low severity, low 
prevalence, 100 
000€
1.642538 78%
2 Low
low severity, low 
prevalence, 100 
000€
1.27 7% Low
low severity, low 
prevalence, 100 
000€
0.38 22%
Choice set four
1 High
low severity, low 
prevalence, 100 
000€
3.915672 48% High
low severity, low 
prevalence, 100 
000€
1. 
642538 31%
2 Low
high severity, 
high prevalence, 
500€
3.980664 52% Low
high severity, 
high preva-
lence, 500€
2.445915 69%
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APPENDIX I
FIGURE 8 . QUESTIONNAIRE (ORIGINAL)
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Caro cidadão, 
Convido-o a participar numa investigação da Universidade do Minho. Para isso peço-lhe que 
responda ao questionário que encontra nas páginas seguintes. Esta investigação faz parte de uma 
tese de mestrado em Economia e Política da Saúde, sob o tema “Preferências Sociais no 
financiamento de medicamentos em Portugal”.  
O objetivo deste estudo é recolher informação sobre as preferências da população no que 
respeita ao financiamento dos medicamentos.  
Como sabe, em Portugal os cuidados de saúde são, na sua maior parte, financiados pelo estado, 
com recurso aos impostos que cada contribuinte paga. Assim queremos saber como acha que 
estes recursos deviam ser usados, nomeadamente na comparticipação de medicamentos 
A sua colaboração é valiosa e imprescindível para que a que investigação prossiga. 
Peço que leia com atenção toda a informação que fornecemos. Os textos que lhe apresentamos 
servem de introdução às perguntas e tornarão mais fácil a compreensão e conclusão deste 
questionário. O questionário tem impressão frente e verso.
Para facilitar a devolução do questionário à Universidade do Minho, enviamos-lhe nesta carta um 
envelope sem franquia (não precisa de selo). Por favor, devolva o questionário devidamente 
preenchido neste envelope, dentro de duas semanas.
Os seus dados são confidenciais e manter-se-ão protegidos. Os resultados deste estudo serão 
utilizados apenas para esta investigação e não têm qualquer envolvimento político.  
Agradeço desde já a disponibilidade. Para qualquer questão, por favor contacte-me através do 
endereço eletrónico pg19509@uminho.pt.
Atenciosamente, 
(Magda Aguiar)                                                                                                               (Paula Benesch)                                       
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Parte 1. O sistema de comparticipação de medicamentos
Discordo 
totalmente Discordo 
Não tenho 
a certeza Concordo
Concordo 
totalmente 
Compreendo o sistema de 
comparticipação de 
medicamentos 
     
O sistema de 
comparticipação de 
medicamentos devia ser 
mais simples 
     
Apenas os medicamentos 
mais eficazes deviam ser 
comparticipados 
     
O Estado gasta demasiado 
dinheiro com a 
comparticipação de 
medicamentos 
     
Apenas os medicamentos 
mais baratos deviam ser 
comparticipados 
     
Apenas se devia 
comparticipar os 
medicamentos aos 
indivíduos com mais 
dificuldades económicas 
     
Devia haver um limite 
máximo de 
comparticipação por 
indivíduo 
     
A comparticipação devia 
basear-se nos gastos 
mensais com 
medicamentos (ajudar 
mais quem gasta mais) 
     
Não se devia comparticipar 
medicamentos a indivíduos 
com hábitos pouco 
saudáveis 
     
TODOS os medicamentos 
deviam ser 
comparticipados 
     
Os medicamentos de 
venda livre (não sujeitos a 
receita médica) deviam ser 
comparticipados 
     
Queremos saber o que pensa do sistema de comparticipação de medicamentos português. Por favor 
selecione (  ), em cada linha, uma opção: 
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Parte 2. Escolher entre diferentes medicamentos 
Por favor LEIA COM ATENÇÃO: 
Nesta segunda parte, queremos saber como gostava de distribuir os recursos disponíveis para o 
financiamento de medicamentos em Portugal.  
Perante um orçamento limitado, o Ministério da Saúde é forçado a fazer escolhas, incluindo sobre 
quais os medicamentos que devem ser comparticipados. 
Os critérios atualmente considerados para apoiar esta decisão são a eficácia do medicamento e o 
preço do medicamento. Os medicamentos que não apresentam eficácia comprovada ou que sejam 
considerados caros, em comparação com os que já existem no mercado, não recebem 
comparticipação.  
Nas próximas perguntas, pedimos-lhe que imagine que lhe cabe a si esta decisão. Assim, deve 
escolher, em cada pergunta, que medicamento acha que o governo DEVE COMPARTICIPAR, 
tendo em conta as características que considera mais importantes. Lembre-se que apenas um dos 
medicamentos pode permanecer na lista de medicamentos comparticipados. Cada pergunta é 
independente o que significa que ao longo do questionário os medicamentos A e B são diferentes 
Entendemos que algumas respostas serão difíceis mas lembre-se que não existem respostas 
certas nem erradas. É a sua opinião que conta! 
NA PÁGINA SEGUINTE ESTÃO DESCRITOS OS CRITÉRIOS A TER EM CONTA PARA 
A SUA DECISÃO. 
POR FAVOR LEIA CUIDADOSAMENTE A PÁGINA SEGUINTE ANTES DE RESPONDER 
AO RESTO DO QUESTIONÁRIO. 
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Critérios apresentados 
Para que possa escolher entre os dois medicamentos, descrevemos-lhe as características 
que deve ter em conta: 
• Gravidade da doença - Grau de incapacidade provocado pela doença. Quanto mais 
incapacitante for a doença, mais grave ela é. 
• Prevalência da doença - Número total de casos, numa dada população, num determinado 
tempo. 
• Eficácia do medicamento - corresponde à capacidade de o medicamento produzir os 
resultados pretendidos. 
 
• Custo para o Estado - quanto o Estado gasta, por pessoa tratada, ao decidir comparticipar 
o medicamento (500€,1.000€, 5.000€, 10.000€, 50.000€, 100.000€) 
NÍVEIS EXEMPLOS 
Doença ligeira 
Eczema, dor de costas 
passageira (aguda), 
enxaqueca 
Doença grave Tuberculose, artrite reumatoide moderada 
Doença muito grave Esclerose múltipla progressiva, cancro. 
NÍVEIS  DESCRIÇÃO EXEMPLOS 
Elevada  
(mais de 5%) 
Mais de 5 em cada 100 
pessoas têm esta doença 
 Hipertensão arterial 
Doença reumática 
Moderada  
(entre 1% e 5%) 
Entre 1 e 5 pessoas em 
cada 100 têm esta doença 
Tumor maligno 
 Bronquite 
Baixa  
(menor de 1%) 
Menos de 1 em cada 100 
pessoas têm esta doença 
 Insuficiência Renal 
Enfarte Agudo Miocárdio 
NÍVEIS EXEMPLOS 
Muito eficaz 
Este medicamento faz, 
na maioria das vezes, o 
efeito pretendido 
Moderadamente 
eficaz 
Nem sempre este 
medicamento faz o 
efeito pretendido 
Pouco eficaz 
Muitas vezes este 
medicamento não faz o 
efeito pretendido 
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EXEMPLO 
Por favor compare os seguintes medicamentos e selecione qual acha que deve ser 
COMPARTICIPADO 
Medicamento A Medicamento B
Gravidade da doença Doença grave Doença ligeira 
Prevalência Moderada Elevada 
Eficácia do medicamento Moderadamente eficaz 
Moderadamente 
eficaz 
Custo para o Estado 1 000€ 500€ 
Medicamento A Medicamento B
Por favor marque uma 
das opções    
Apenas um dos medicamentos pode entrar na lista de medicamentos 
comparticipados.  
Ao escolher o medicamento B, este indivíduo prefere comparticipar um 
medicamento com eficácia moderada para tratar uma doença ligeira (mínima 
gravidade). Esta doença tem elevada prevalência. A decisão de comparticipar 
este medicamento vai custar ao estado 500€ por pessoa tratada. 
Ao selecionar o medicamento B este indivíduo escolheu não comparticipar o 
medicamento A.
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1. Por favor compare os seguintes medicamentos e selecione qual acha que deve ser 
COMPARTICIPADO: 
Medicamento A Medicamento B
Gravidade da doença  Doença ligeira Doença grave  
Prevalência Alta Moderada 
Eficácia do medicamento Pouco eficaz Moderadamente eficaz 
Custo para o estado (por 
pessoa tratada) 500 € 1 000€ 
Medicamento A Medicamento B
Por favor selecione uma 
opção    
2. Por favor compare os seguintes medicamentos e selecione qual acha que deve ser 
COMPARTICIPADO: 
Medicamento A Medicamento B
Gravidade da doença Doença muito grave  Doença ligeira 
Prevalência Alta  Baixa 
Eficácia do medicamento Moderadamente eficaz Muito eficaz 
Custo para o estado (por 
pessoa tratada) 1 000€  10 000€ 
Medicamento A Medicamento B
Por favor selecione uma 
opção    
3. Por favor compare os seguintes medicamentos e selecione qual acha que deve ser 
COMPARTICIPADO: 
Medicamento A Medicamento B
Gravidade da doença Doença muito grave  Doença ligeira 
Prevalência Moderada  Baixa 
Eficácia do medicamento Pouco eficaz  Moderadamente eficaz 
Custo para o estado (por 
pessoa tratada) 5 000€  10 000€ 
Medicamento A Medicamento B
Por favor selecione uma 
opção    
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4. Por favor compare os seguintes medicamentos e selecione qual acha que deve ser 
COMPARTICIPADO: 
Medicamento A Medicamento B
Gravidade da doença Doença ligeira  Doença grave 
Prevalência Baixa  Moderada 
Eficácia do medicamento Muito eficaz  Pouco eficaz 
Custo para o estado (por 
pessoa tratada) 10 000€  50 000€ 
Medicamento A Medicamento B
Por favor selecione uma 
opção    
5. Por favor compare os seguintes medicamentos e selecione qual acha que deve ser 
COMPARTICIPADO: 
Medicamento A Medicamento B
Gravidade da doença Doença grave  Doença muito grave 
Prevalência Baixa  Moderada 
Eficácia do medicamento Moderadamente eficaz Muito eficaz 
Custo para o estado (por 
pessoa tratada) 50 000€  100 000€ 
Medicamento A Medicamento B
Por favor selecione uma 
opção    
6. Por favor compare os seguintes medicamentos e selecione qual acha que deve ser 
COMPARTICIPADO: 
Medicamento A Medicamento B
Gravidade da doença Doença grave  Doença muito grave 
Prevalência Moderada  Baixa 
Eficácia do medicamento Muito eficaz  Pouco eficaz 
Custo para o estado (por 
pessoa tratada) 100 000€  500€ 
Medicamento A Medicamento B
Por favor selecione uma 
opção    
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7. Por favor compare os seguintes medicamentos e selecione qual acha que deve ser 
COMPARTICIPADO: 
Medicamento A Medicamento B
Gravidade da doença Grave  Doença muito grave 
Prevalência Moderada  Baixa 
Eficácia do medicamento Moderada  Muito eficaz 
Custo para o estado (por 
pessoa tratada) 500€  1 000€ 
Medicamento A Medicamento B
Por favor selecione uma 
opção    
8. Por favor compare os seguintes medicamentos e selecione qual acha que deve ser 
COMPARTICIPADO: 
Medicamento A Medicamento B
Gravidade da doença Doença ligeira  Doença grave 
Prevalência Moderada  Baixa 
Eficácia do medicamento Moderadamente eficaz Pouco eficaz 
Custo para o estado (por 
pessoa tratada) 1 000€  5 000€ 
Medicamento A Medicamento B
Por favor selecione uma 
opção    
9. Por favor compare os seguintes medicamentos e selecione qual acha que deve ser 
COMPARTICIPADO: 
Medicamento A Medicamento B
Gravidade da doença Doença ligeira  Doença grave 
Prevalência Baixa  Alta 
Eficácia do medicamento Moderadamente eficaz Muito eficaz 
Custo para o estado (por 
pessoa tratada) 1 000€  50 000€ 
Medicamento A Medicamento B
Por favor selecione uma 
opção    
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10. Por compare os seguintes medicamentos e selecione qual acha que deve ser 
COMPARTICIPADO: 
Medicamento A Medicamento B
Gravidade da doença Doença grave  Doença muito grave 
Prevalência Alta  Moderada 
Eficácia do medicamento Pouco eficaz  Moderadamente eficaz 
Custo para o estado (por 
pessoa tratada) 10 000€  50 000€ 
Medicamento A Medicamento B
Por favor selecione uma 
opção    
11. Por favor compare os seguintes medicamentos e selecione qual acha que deve ser 
COMPARTICIPADO: 
Medicamento A Medicamento B
Gravidade da doença Doença muito grave  Doença ligeira 
Prevalência Alta  Moderada 
Eficácia do medicamento Muito eficaz  Pouco eficaz 
Custo para o estado (por 
pessoa tratada) 50 000€  100 000€ 
Medicamento A Medicamento B
Por favor selecione uma 
opção    
12. Por favor compare os seguintes medicamentos e selecione qual acha que deve ser 
COMPARTICIPADO: 
Medicamento A Medicamento B
Gravidade da doença Doença muito grave  Doença ligeira 
Prevalência Baixa  Alta 
Eficácia do medicamento Pouco eficaz  Moderadamente eficaz 
Custo para o estado (por 
pessoa tratada) 100 000€  500€ 
Medicamento A Medicamento B
Por favor selecione uma 
opção    
98
10 
 
13. Por favor compare os seguintes medicamentos e selecione qual acha que deve ser 
COMPARTICIPADO: 
Medicamento A Medicamento B
Gravidade da doença Doença muito grave  Doença ligeira 
Prevalência Baixa  Alta 
Eficácia do medicamento Muito eficaz  Moderadamente eficaz 
Custo para o estado (por 
pessoa tratada) 500€  1 000€ 
Medicamento A Medicamento B
Por favor selecione uma 
opção    
14. Por favor compare os seguintes medicamentos e selecione qual acha que deve ser 
COMPARTICIPADO: 
Medicamento A Medicamento B
Gravidade da doença Doença grave  Doença muito grave 
Prevalência Baixa  Alta 
Eficácia do medicamento Pouco eficaz  Moderadamente eficaz 
Custo para o estado (por 
pessoa tratada) 1 000€  50 000€ 
Medicamento A Medicamento B
Por favor selecione uma 
opção    
15. Por favor compare os seguintes medicamentos e selecione qual acha que deve ser 
COMPARTICIPADO: 
Medicamento A Medicamento B
Gravidade da doença Doença grave  Doença muito grave 
Prevalência Alta  Moderada 
Eficácia do medicamento Muito eficaz  Pouco eficaz 
Custo para o estado (por 
pessoa tratada) 5 000€  10 000€ 
Medicamento A Medicamento B
Por favor selecione uma 
opção    
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16. Por favor compare os seguintes medicamentos e selecione qual acha que deve ser 
COMPARTICIPADO: 
Medicamento A Medicamento B
Gravidade da doença Doença muito grave  Doença ligeira 
Prevalência Moderada  Baixa 
Eficácia do medicamento Moderadamente eficaz Muito eficaz 
Custo para o estado (por 
pessoa tratada) 10 000€  50 000€ 
Medicamento A Medicamento B
Por favor selecione uma 
opção    
17. Por favor compare os seguintes medicamentos e selecione qual acha que deve ser 
COMPARTICIPADO: 
Medicamento A Medicamento B
Gravidade da doença Doença ligeira  Doença grave 
Prevalência Moderada  Baixa 
Eficácia do medicamento Moderadamente eficaz Muito eficaz 
Custo para o estado (por 
pessoa tratada) 50 000€  100 000€ 
Medicamento A Medicamento B
Por favor selecione uma 
opção    
18. Por favor compare os seguintes medicamentos e selecione qual acha que deve ser 
COMPARTICIPADO: 
Medicamento A Medicamento B
Gravidade da doença Doença ligeira  Doença grave 
Prevalência Alta  Moderada 
Eficácia do medicamento Pouco eficaz  Moderadamente eficaz 
Custo para o estado (por 
pessoa tratada) 100 000€  500€ 
Medicamento A Medicamento B
Por favor selecione uma 
opção    
100
12 
 
Parte 3. Sobre si: (Para melhor compreendermos as suas respostas, gostaríamos de lhe 
colocar algumas perguntas mais pessoais)
1. Que idade tem? 
    Prefiro não dizer 
2. Qual é o seu género? 
Masculino Feminino 
  
3. Que habilitações literárias possui? Por favor selecione (  ) apenas uma opção.
 Ensino Superior 
 Ensino secundário (até ao 12º 
 Ensino Básico (até ao 9º ano) 
 Ensino Primário (até à 4ª classe)  
 Nunca estudei  
 Prefiro não dizer 
 
4. Como classifica o seu estado geral de saúde? Por favor selecione ( ) apenas uma 
opção. 
 Muito bom Bom Razoável Mau Muito mau 
      
5. Sofre de alguma doença crónica? Por favor selecione ( ) apenas uma opção. 
Sim, uma Sim, mais do que uma Não 
   
6. Neste momento está: Por favor selecione ( ) as opções que se aplicam.
 Profissionalmente ativo  Desempregado 
 A estudar  Incapacitado para trabalhar por doença 
 Reformado  De baixa/licença médica 
 Outro. Por favor diga-nos qual:  __________________________________________  
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7. Qual destas opções representa o seu salário mensal, incluindo todos os benefícios e 
depois de todas as deduções (salário mensal líquido)? Por favor selecione  
 Não tenho rendimentos 
 Até 485,99€  
 Entre 486€ e 900,99€ 
 Entre 901€ e 1455,99€ 
 Entre 1456€ e 1940,99€  
 Entre 1941€ e 2425,99€  
 Entre 2426€ e 3395,99€ 
 Mais de 3396€ 
 Prefiro não dizer 
8. Em média, quanto gasta por mês na compra de medicamentos? Por favor selecione   
 Não tenho gastos com medicamentos  
 Até 5,99€  
 Entre 6€ e 25,99€ 
 Entre 26€ e 50,99€ 
 Entre 51€ e 75,99€  
 Entre 76€ e 100,99€  
 Ente 101€ e 150,99€ 
 Mais de 151€  
 Não sei 
9. Beneficia de algum subsistema de saúde? Por favor selecione  apenas uma opção 
(Nota: exemplos de subsistemas são: ADSE, SAMS, ADM, SADPSP/GNR, entre outros) 
 Sim Não Não sei 
    
10. Possui algum seguro privado de saúde que cubra despesas com medicamentos? Por 
favor selecione () apenas uma opção.
 Sim Não  
   
11. Beneficia de algum regime especial de comparticipação (pensionistas, lúpus, 
paramiloidose, artrite reumatoide)? Por favor selecione () apenas uma opção.
 Sim Não Não sei 
    
